Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 749 | 2024 | 10900 | 42.560 |
Why?
|
Stroke Volume | 512 | 2024 | 5007 | 28.770 |
Why?
|
Tetrazoles | 175 | 2024 | 835 | 22.380 |
Why?
|
Angiotensin Receptor Antagonists | 156 | 2024 | 924 | 19.050 |
Why?
|
Ventricular Function, Left | 234 | 2024 | 3670 | 16.780 |
Why?
|
Ventricular Dysfunction, Left | 153 | 2024 | 2073 | 16.320 |
Why?
|
Biphenyl Compounds | 169 | 2024 | 913 | 15.790 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 125 | 2024 | 1518 | 11.050 |
Why?
|
Enalapril | 50 | 2024 | 327 | 10.570 |
Why?
|
Neprilysin | 58 | 2024 | 439 | 10.410 |
Why?
|
Spironolactone | 51 | 2024 | 382 | 9.540 |
Why?
|
Natriuretic Peptide, Brain | 97 | 2024 | 1573 | 9.500 |
Why?
|
Glucosides | 61 | 2024 | 451 | 8.800 |
Why?
|
Benzhydryl Compounds | 70 | 2024 | 845 | 8.280 |
Why?
|
Drug Combinations | 132 | 2024 | 1959 | 8.070 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 60 | 2021 | 451 | 7.740 |
Why?
|
Ventricular Remodeling | 64 | 2023 | 1224 | 7.600 |
Why?
|
Hypertrophy, Left Ventricular | 39 | 2023 | 859 | 5.770 |
Why?
|
Peptide Fragments | 82 | 2024 | 5097 | 5.640 |
Why?
|
Cardiac Resynchronization Therapy | 57 | 2020 | 531 | 5.330 |
Why?
|
Prealbumin | 17 | 2024 | 210 | 5.240 |
Why?
|
Myocardial Infarction | 127 | 2024 | 11727 | 5.200 |
Why?
|
Hospitalization | 156 | 2024 | 10262 | 5.020 |
Why?
|
Echocardiography | 123 | 2022 | 5102 | 4.990 |
Why?
|
Heart Failure, Diastolic | 13 | 2023 | 69 | 4.950 |
Why?
|
Defibrillators, Implantable | 58 | 2021 | 1440 | 4.670 |
Why?
|
Atrial Fibrillation | 56 | 2023 | 5034 | 4.420 |
Why?
|
Renal Insufficiency, Chronic | 48 | 2023 | 2208 | 4.410 |
Why?
|
Atherosclerosis | 42 | 2023 | 3445 | 4.120 |
Why?
|
Hypertension | 53 | 2023 | 8480 | 3.970 |
Why?
|
Hematinics | 24 | 2023 | 281 | 3.910 |
Why?
|
Heart Ventricles | 59 | 2022 | 3821 | 3.840 |
Why?
|
Cardiovascular Diseases | 124 | 2023 | 15165 | 3.830 |
Why?
|
Aged | 582 | 2024 | 163280 | 3.820 |
Why?
|
Antihypertensive Agents | 48 | 2023 | 2046 | 3.750 |
Why?
|
Humans | 1189 | 2024 | 744343 | 3.740 |
Why?
|
Amyloid Neuropathies, Familial | 10 | 2024 | 138 | 3.710 |
Why?
|
Benzimidazoles | 34 | 2020 | 850 | 3.650 |
Why?
|
Troponin T | 28 | 2023 | 754 | 3.460 |
Why?
|
Blood Pressure | 59 | 2023 | 8554 | 3.450 |
Why?
|
Influenza, Human | 26 | 2024 | 1479 | 3.370 |
Why?
|
Heart Atria | 40 | 2023 | 1357 | 3.290 |
Why?
|
Diabetes Mellitus, Type 2 | 73 | 2024 | 11725 | 3.280 |
Why?
|
Prognosis | 206 | 2024 | 29063 | 3.240 |
Why?
|
Male | 740 | 2024 | 350118 | 3.230 |
Why?
|
Double-Blind Method | 142 | 2024 | 12026 | 3.210 |
Why?
|
Influenza Vaccines | 22 | 2024 | 738 | 3.170 |
Why?
|
Middle Aged | 546 | 2023 | 213383 | 3.100 |
Why?
|
Fumarates | 27 | 2020 | 132 | 3.080 |
Why?
|
Echocardiography, Doppler | 25 | 2020 | 935 | 3.070 |
Why?
|
Atrial Function, Left | 18 | 2023 | 173 | 3.060 |
Why?
|
Female | 746 | 2024 | 380194 | 3.050 |
Why?
|
Anemia | 32 | 2023 | 1506 | 2.990 |
Why?
|
Valine | 28 | 2014 | 413 | 2.920 |
Why?
|
Urea | 15 | 2024 | 450 | 2.920 |
Why?
|
Erythropoietin | 17 | 2023 | 726 | 2.870 |
Why?
|
Cardiomyopathies | 24 | 2023 | 1912 | 2.780 |
Why?
|
Randomized Controlled Trials as Topic | 82 | 2024 | 9959 | 2.770 |
Why?
|
Diastole | 27 | 2021 | 791 | 2.660 |
Why?
|
Amides | 27 | 2020 | 459 | 2.630 |
Why?
|
Glomerular Filtration Rate | 52 | 2024 | 2170 | 2.510 |
Why?
|
Death, Sudden, Cardiac | 30 | 2021 | 1541 | 2.500 |
Why?
|
Renin-Angiotensin System | 20 | 2024 | 759 | 2.400 |
Why?
|
Treatment Outcome | 233 | 2024 | 63114 | 2.270 |
Why?
|
Heart Failure, Systolic | 9 | 2023 | 126 | 2.210 |
Why?
|
Risk Factors | 227 | 2023 | 72290 | 2.190 |
Why?
|
Aged, 80 and over | 152 | 2023 | 57776 | 2.120 |
Why?
|
Prospective Studies | 160 | 2024 | 53288 | 2.090 |
Why?
|
Risk Assessment | 103 | 2022 | 23338 | 2.010 |
Why?
|
Diabetes Mellitus | 30 | 2024 | 5751 | 1.980 |
Why?
|
Diuretics | 20 | 2023 | 592 | 1.930 |
Why?
|
Cause of Death | 48 | 2021 | 3584 | 1.900 |
Why?
|
Kidney | 34 | 2023 | 7186 | 1.890 |
Why?
|
Natriuretic Peptides | 11 | 2023 | 150 | 1.850 |
Why?
|
Prediabetic State | 8 | 2023 | 499 | 1.820 |
Why?
|
Proportional Hazards Models | 91 | 2023 | 12354 | 1.800 |
Why?
|
Bundle-Branch Block | 20 | 2020 | 270 | 1.770 |
Why?
|
Kidney Diseases | 24 | 2023 | 2149 | 1.740 |
Why?
|
Follow-Up Studies | 130 | 2022 | 39050 | 1.720 |
Why?
|
Ventricular Dysfunction, Right | 14 | 2023 | 581 | 1.700 |
Why?
|
Systole | 27 | 2023 | 958 | 1.690 |
Why?
|
Renin | 17 | 2022 | 642 | 1.670 |
Why?
|
Amyloidosis | 8 | 2023 | 795 | 1.630 |
Why?
|
Pulmonary Edema | 8 | 2024 | 414 | 1.630 |
Why?
|
Heart | 16 | 2023 | 4467 | 1.610 |
Why?
|
Cardiovascular Agents | 15 | 2022 | 850 | 1.610 |
Why?
|
Hyperkalemia | 14 | 2023 | 218 | 1.590 |
Why?
|
Captopril | 16 | 2015 | 272 | 1.570 |
Why?
|
Quality of Life | 56 | 2023 | 12804 | 1.540 |
Why?
|
Stroke | 51 | 2023 | 9981 | 1.510 |
Why?
|
Ramipril | 15 | 2024 | 95 | 1.500 |
Why?
|
Kidney Failure, Chronic | 21 | 2023 | 2538 | 1.460 |
Why?
|
Endpoint Determination | 15 | 2020 | 601 | 1.460 |
Why?
|
Clinical Trials as Topic | 40 | 2024 | 7913 | 1.440 |
Why?
|
Albuminuria | 15 | 2023 | 682 | 1.440 |
Why?
|
Time Factors | 117 | 2023 | 40075 | 1.420 |
Why?
|
Protease Inhibitors | 6 | 2020 | 791 | 1.420 |
Why?
|
Diabetes Complications | 14 | 2020 | 1359 | 1.410 |
Why?
|
Electric Countershock | 14 | 2020 | 534 | 1.350 |
Why?
|
Sex Factors | 38 | 2022 | 10397 | 1.330 |
Why?
|
Myocardial Contraction | 19 | 2021 | 1585 | 1.320 |
Why?
|
Heart Rate | 15 | 2023 | 4091 | 1.320 |
Why?
|
Angiotensins | 13 | 2024 | 151 | 1.300 |
Why?
|
United States | 132 | 2024 | 69872 | 1.290 |
Why?
|
Coronavirus Infections | 12 | 2020 | 3133 | 1.250 |
Why?
|
Tachycardia, Ventricular | 19 | 2023 | 1273 | 1.240 |
Why?
|
Survival Rate | 67 | 2022 | 12788 | 1.240 |
Why?
|
Pneumonia, Viral | 12 | 2020 | 3240 | 1.240 |
Why?
|
Dipeptides | 3 | 2019 | 409 | 1.210 |
Why?
|
Electrocardiography | 37 | 2021 | 6442 | 1.200 |
Why?
|
Incidence | 64 | 2023 | 20947 | 1.190 |
Why?
|
Ventricular Pressure | 3 | 2021 | 199 | 1.190 |
Why?
|
Cardiomyopathy, Hypertrophic | 14 | 2023 | 1265 | 1.130 |
Why?
|
Blood Glucose | 16 | 2023 | 6256 | 1.120 |
Why?
|
Kaplan-Meier Estimate | 52 | 2020 | 6538 | 1.110 |
Why?
|
Research Design | 24 | 2023 | 5987 | 1.090 |
Why?
|
Predictive Value of Tests | 56 | 2023 | 15076 | 1.060 |
Why?
|
Ventricular Function, Right | 10 | 2023 | 591 | 1.050 |
Why?
|
Heart Diseases | 7 | 2022 | 2788 | 1.050 |
Why?
|
Troponin I | 6 | 2021 | 619 | 1.040 |
Why?
|
Comorbidity | 45 | 2023 | 10388 | 1.030 |
Why?
|
Diabetic Angiopathies | 7 | 2020 | 818 | 1.020 |
Why?
|
Cardiomyopathy, Restrictive | 2 | 2015 | 60 | 1.000 |
Why?
|
Ventricular Fibrillation | 11 | 2023 | 538 | 1.000 |
Why?
|
Europe | 29 | 2023 | 3339 | 0.990 |
Why?
|
RNA, Small Interfering | 5 | 2023 | 3505 | 0.990 |
Why?
|
Furosemide | 4 | 2023 | 167 | 0.980 |
Why?
|
Creatinine | 29 | 2024 | 1919 | 0.960 |
Why?
|
Cyclooxygenase 2 Inhibitors | 6 | 2013 | 320 | 0.960 |
Why?
|
Drug Therapy, Combination | 38 | 2022 | 6489 | 0.960 |
Why?
|
Extravascular Lung Water | 2 | 2014 | 20 | 0.950 |
Why?
|
Cardiotonic Agents | 10 | 2020 | 535 | 0.940 |
Why?
|
Cardiac Myosins | 6 | 2021 | 117 | 0.920 |
Why?
|
Dietary Carbohydrates | 3 | 2018 | 906 | 0.920 |
Why?
|
Health Status | 17 | 2023 | 4034 | 0.910 |
Why?
|
Coronary Disease | 17 | 2019 | 6077 | 0.910 |
Why?
|
Malnutrition | 2 | 2019 | 625 | 0.870 |
Why?
|
Multivariate Analysis | 45 | 2020 | 12245 | 0.870 |
Why?
|
Smoking | 12 | 2022 | 8987 | 0.870 |
Why?
|
Myocardium | 20 | 2023 | 4776 | 0.870 |
Why?
|
Ultrasonography | 37 | 2021 | 5985 | 0.860 |
Why?
|
Exercise Tolerance | 11 | 2022 | 770 | 0.860 |
Why?
|
Amyloidosis, Familial | 2 | 2023 | 13 | 0.860 |
Why?
|
Vaccination | 17 | 2023 | 3278 | 0.850 |
Why?
|
Coronary Artery Disease | 20 | 2023 | 6487 | 0.820 |
Why?
|
Hemoglobins | 12 | 2023 | 1534 | 0.810 |
Why?
|
Barbiturates | 4 | 2022 | 114 | 0.810 |
Why?
|
Obesity | 19 | 2023 | 12745 | 0.810 |
Why?
|
Heterocyclic Compounds, 2-Ring | 5 | 2020 | 22 | 0.810 |
Why?
|
Disease Progression | 43 | 2023 | 13284 | 0.800 |
Why?
|
Severity of Illness Index | 47 | 2021 | 15540 | 0.790 |
Why?
|
Death, Sudden | 4 | 2021 | 302 | 0.790 |
Why?
|
Ergocalciferols | 5 | 2013 | 110 | 0.780 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 10 | 2023 | 3047 | 0.780 |
Why?
|
Alcohol Drinking | 6 | 2019 | 3966 | 0.770 |
Why?
|
Heart Arrest | 9 | 2021 | 1470 | 0.770 |
Why?
|
Dose-Response Relationship, Drug | 30 | 2022 | 10943 | 0.770 |
Why?
|
Pandemics | 17 | 2023 | 8388 | 0.760 |
Why?
|
Age Factors | 36 | 2021 | 18370 | 0.760 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2021 | 841 | 0.750 |
Why?
|
Adrenergic beta-Antagonists | 16 | 2023 | 1240 | 0.750 |
Why?
|
Prevalence | 39 | 2023 | 15226 | 0.740 |
Why?
|
Mitral Valve Insufficiency | 7 | 2022 | 1422 | 0.740 |
Why?
|
Pyridines | 6 | 2019 | 2825 | 0.730 |
Why?
|
Mortality | 12 | 2021 | 2864 | 0.730 |
Why?
|
Cardiology | 8 | 2023 | 1668 | 0.710 |
Why?
|
Cardiac Volume | 6 | 2014 | 210 | 0.700 |
Why?
|
Renal Dialysis | 9 | 2023 | 1786 | 0.700 |
Why?
|
Dyspnea | 5 | 2023 | 1303 | 0.700 |
Why?
|
Drug Labeling | 1 | 2021 | 233 | 0.690 |
Why?
|
Antiemetics | 2 | 2018 | 177 | 0.680 |
Why?
|
Peptidyl-Dipeptidase A | 2 | 2020 | 365 | 0.680 |
Why?
|
Adenosine A1 Receptor Agonists | 1 | 2018 | 12 | 0.670 |
Why?
|
Hyperaldosteronism | 2 | 2022 | 240 | 0.670 |
Why?
|
Uric Acid | 4 | 2023 | 766 | 0.670 |
Why?
|
Migraine Disorders | 14 | 2006 | 1620 | 0.650 |
Why?
|
Hyperemia | 2 | 2019 | 225 | 0.650 |
Why?
|
Body Mass Index | 18 | 2022 | 12720 | 0.650 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 2 | 2022 | 216 | 0.650 |
Why?
|
Sodium-Glucose Transporter 1 | 1 | 2018 | 112 | 0.640 |
Why?
|
North America | 8 | 2020 | 1249 | 0.640 |
Why?
|
Diabetic Nephropathies | 6 | 2023 | 984 | 0.640 |
Why?
|
Blood Pressure Determination | 3 | 2020 | 634 | 0.630 |
Why?
|
Hypotension | 8 | 2023 | 884 | 0.630 |
Why?
|
Cohort Studies | 52 | 2023 | 40561 | 0.620 |
Why?
|
Indoles | 12 | 2019 | 1839 | 0.620 |
Why?
|
Ondansetron | 1 | 2018 | 90 | 0.620 |
Why?
|
Nausea | 2 | 2018 | 673 | 0.610 |
Why?
|
Acute Coronary Syndrome | 11 | 2022 | 2337 | 0.610 |
Why?
|
Apolipoprotein E4 | 1 | 2021 | 668 | 0.610 |
Why?
|
Adiposity | 2 | 2018 | 1807 | 0.600 |
Why?
|
Hemodynamics | 18 | 2021 | 4199 | 0.600 |
Why?
|
Intestinal Absorption | 1 | 2018 | 420 | 0.590 |
Why?
|
Hypoglycemic Agents | 14 | 2024 | 2872 | 0.590 |
Why?
|
Echocardiography, Doppler, Color | 6 | 2014 | 364 | 0.590 |
Why?
|
Sulfonamides | 6 | 2014 | 1938 | 0.590 |
Why?
|
Vascular Diseases | 3 | 2022 | 1161 | 0.590 |
Why?
|
Chronic Disease | 34 | 2023 | 9146 | 0.580 |
Why?
|
Practice Guidelines as Topic | 11 | 2019 | 7279 | 0.560 |
Why?
|
Lung | 13 | 2023 | 9856 | 0.560 |
Why?
|
Ferritins | 3 | 2022 | 590 | 0.550 |
Why?
|
Heart Valve Diseases | 4 | 2022 | 1073 | 0.550 |
Why?
|
Atrial Natriuretic Factor | 6 | 2022 | 393 | 0.550 |
Why?
|
Adult | 135 | 2024 | 214055 | 0.540 |
Why?
|
Retinal Artery | 1 | 2016 | 111 | 0.540 |
Why?
|
Myocardial Revascularization | 6 | 2017 | 841 | 0.540 |
Why?
|
Benzylamines | 3 | 2021 | 223 | 0.540 |
Why?
|
Arrhythmias, Cardiac | 11 | 2022 | 2268 | 0.530 |
Why?
|
Uracil | 3 | 2021 | 165 | 0.530 |
Why?
|
Cardiac Pacing, Artificial | 4 | 2019 | 845 | 0.530 |
Why?
|
Survival Analysis | 26 | 2022 | 10252 | 0.520 |
Why?
|
Glucose Tolerance Test | 1 | 2018 | 1150 | 0.520 |
Why?
|
Plant Stems | 1 | 2015 | 19 | 0.520 |
Why?
|
Cardiac Imaging Techniques | 2 | 2015 | 269 | 0.520 |
Why?
|
Prehypertension | 1 | 2015 | 61 | 0.510 |
Why?
|
Vomiting | 1 | 2018 | 636 | 0.510 |
Why?
|
Saccharum | 1 | 2015 | 17 | 0.510 |
Why?
|
Diabetic Cardiomyopathies | 3 | 2019 | 96 | 0.510 |
Why?
|
Single-Blind Method | 10 | 2019 | 1590 | 0.510 |
Why?
|
Longevity | 2 | 2020 | 1070 | 0.500 |
Why?
|
Hypoglycemia | 1 | 2022 | 861 | 0.500 |
Why?
|
Troponin | 5 | 2019 | 524 | 0.500 |
Why?
|
Genes, Plant | 1 | 2015 | 124 | 0.500 |
Why?
|
Canada | 15 | 2019 | 2065 | 0.500 |
Why?
|
Outpatients | 5 | 2023 | 1486 | 0.500 |
Why?
|
Echocardiography, Three-Dimensional | 3 | 2018 | 591 | 0.490 |
Why?
|
Point-of-Care Systems | 2 | 2014 | 1177 | 0.490 |
Why?
|
Glycine | 4 | 2022 | 671 | 0.490 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1584 | 0.490 |
Why?
|
Placebos | 9 | 2020 | 1676 | 0.490 |
Why?
|
Heart Valve Prosthesis Implantation | 5 | 2023 | 1536 | 0.490 |
Why?
|
Receptors, Angiotensin | 7 | 2024 | 142 | 0.490 |
Why?
|
Losartan | 4 | 2012 | 299 | 0.480 |
Why?
|
Myocardial Ischemia | 8 | 2023 | 2148 | 0.480 |
Why?
|
Linear Models | 17 | 2019 | 5952 | 0.480 |
Why?
|
Leprosy | 3 | 2000 | 124 | 0.480 |
Why?
|
Sucrose | 1 | 2015 | 164 | 0.480 |
Why?
|
Hypokalemia | 6 | 2019 | 153 | 0.480 |
Why?
|
Multicenter Studies as Topic | 11 | 2022 | 1677 | 0.480 |
Why?
|
Exercise | 6 | 2023 | 5615 | 0.480 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 154 | 0.470 |
Why?
|
Internationality | 7 | 2019 | 1003 | 0.470 |
Why?
|
Retinal Vessels | 1 | 2019 | 772 | 0.470 |
Why?
|
Delivery, Obstetric | 1 | 2021 | 906 | 0.470 |
Why?
|
Heart Function Tests | 3 | 2012 | 330 | 0.460 |
Why?
|
Pyrazoles | 5 | 2016 | 1972 | 0.460 |
Why?
|
Galectin 3 | 2 | 2016 | 227 | 0.460 |
Why?
|
Cardiac Output, Low | 4 | 2006 | 195 | 0.460 |
Why?
|
Chi-Square Distribution | 12 | 2017 | 3508 | 0.460 |
Why?
|
Vasodilator Agents | 5 | 2023 | 977 | 0.450 |
Why?
|
Pyrimidines | 7 | 2020 | 2942 | 0.440 |
Why?
|
Hospital Mortality | 11 | 2023 | 5317 | 0.440 |
Why?
|
Hypertrophy, Right Ventricular | 3 | 2015 | 110 | 0.440 |
Why?
|
Polyneuropathies | 4 | 2024 | 137 | 0.440 |
Why?
|
Aftercare | 6 | 2023 | 866 | 0.440 |
Why?
|
Health Status Indicators | 3 | 2015 | 969 | 0.430 |
Why?
|
India | 20 | 2012 | 2197 | 0.430 |
Why?
|
Plant Proteins | 1 | 2015 | 364 | 0.430 |
Why?
|
Models, Cardiovascular | 3 | 2012 | 996 | 0.430 |
Why?
|
Organ Size | 14 | 2022 | 2252 | 0.420 |
Why?
|
Registries | 13 | 2023 | 8089 | 0.420 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 135 | 0.420 |
Why?
|
3-Iodobenzylguanidine | 1 | 2012 | 115 | 0.410 |
Why?
|
Retrospective Studies | 57 | 2023 | 77449 | 0.410 |
Why?
|
Recurrence | 17 | 2020 | 8340 | 0.410 |
Why?
|
Headache | 8 | 2001 | 1226 | 0.410 |
Why?
|
Risk | 19 | 2017 | 9687 | 0.410 |
Why?
|
Nitroprusside | 1 | 2012 | 275 | 0.410 |
Why?
|
Sodium | 11 | 2023 | 1623 | 0.400 |
Why?
|
Population Surveillance | 5 | 2017 | 2616 | 0.400 |
Why?
|
Social Behavior | 1 | 2018 | 1127 | 0.400 |
Why?
|
Morbidity | 13 | 2020 | 1769 | 0.400 |
Why?
|
Hypercholesterolemia | 2 | 2018 | 1151 | 0.400 |
Why?
|
Critical Care | 2 | 2021 | 2647 | 0.390 |
Why?
|
Cost of Illness | 2 | 2020 | 1859 | 0.390 |
Why?
|
Sympathetic Nervous System | 2 | 2020 | 514 | 0.390 |
Why?
|
Cardiomegaly | 4 | 2019 | 620 | 0.390 |
Why?
|
Organ Transplantation | 1 | 2021 | 1139 | 0.390 |
Why?
|
Dexamethasone | 1 | 2018 | 1951 | 0.390 |
Why?
|
Motor Activity | 3 | 2015 | 2714 | 0.380 |
Why?
|
New York | 3 | 2023 | 886 | 0.380 |
Why?
|
Death | 4 | 2020 | 678 | 0.380 |
Why?
|
Heart Conduction System | 5 | 2020 | 1047 | 0.380 |
Why?
|
Cardiomyopathy, Dilated | 6 | 2023 | 851 | 0.380 |
Why?
|
Inpatients | 4 | 2023 | 2518 | 0.370 |
Why?
|
Patient Discharge | 8 | 2023 | 3313 | 0.370 |
Why?
|
Elasticity Imaging Techniques | 2 | 2013 | 388 | 0.370 |
Why?
|
Hematopoietic Stem Cell Transplantation | 8 | 2023 | 5442 | 0.370 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2021 | 2026 | 0.370 |
Why?
|
Health Status Disparities | 5 | 2020 | 1797 | 0.370 |
Why?
|
Pulmonary Embolism | 4 | 2012 | 2376 | 0.370 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 7 | 2013 | 2282 | 0.370 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2021 | 3327 | 0.360 |
Why?
|
Tricuspid Valve Insufficiency | 3 | 2024 | 349 | 0.360 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2009 | 1873 | 0.360 |
Why?
|
alpha-Galactosidase | 1 | 2010 | 57 | 0.360 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2023 | 176 | 0.360 |
Why?
|
Potassium | 8 | 2021 | 1336 | 0.360 |
Why?
|
Metformin | 3 | 2023 | 835 | 0.350 |
Why?
|
Polypharmacy | 2 | 2023 | 294 | 0.350 |
Why?
|
Hypertension, Pulmonary | 8 | 2020 | 1537 | 0.350 |
Why?
|
Cardiovascular System | 6 | 2023 | 832 | 0.350 |
Why?
|
Argentina | 4 | 2018 | 232 | 0.350 |
Why?
|
Graft vs Host Disease | 7 | 2023 | 2957 | 0.350 |
Why?
|
Prostaglandin Antagonists | 1 | 2009 | 30 | 0.340 |
Why?
|
P-Selectin | 2 | 2023 | 600 | 0.340 |
Why?
|
Receptors, Calcitriol | 2 | 2011 | 350 | 0.340 |
Why?
|
Fabry Disease | 1 | 2010 | 90 | 0.340 |
Why?
|
Sex Distribution | 7 | 2015 | 2297 | 0.330 |
Why?
|
Cross-Sectional Studies | 21 | 2023 | 25043 | 0.320 |
Why?
|
HIV Infections | 15 | 2012 | 16718 | 0.320 |
Why?
|
Recovery of Function | 10 | 2020 | 2925 | 0.320 |
Why?
|
Angioedema | 2 | 2020 | 187 | 0.320 |
Why?
|
Physical Examination | 4 | 2019 | 1237 | 0.320 |
Why?
|
Vagus Nerve Stimulation | 3 | 2017 | 199 | 0.310 |
Why?
|
Aging | 3 | 2016 | 8664 | 0.310 |
Why?
|
Sex Characteristics | 6 | 2023 | 2585 | 0.310 |
Why?
|
Reproducibility of Results | 19 | 2022 | 19905 | 0.310 |
Why?
|
Denmark | 8 | 2023 | 738 | 0.310 |
Why?
|
Prostaglandins | 1 | 2009 | 405 | 0.310 |
Why?
|
Chagas Cardiomyopathy | 2 | 2018 | 72 | 0.310 |
Why?
|
Aortic Valve | 2 | 2018 | 1922 | 0.310 |
Why?
|
Vasodilation | 1 | 2012 | 944 | 0.300 |
Why?
|
Extracellular Matrix | 5 | 2020 | 1741 | 0.300 |
Why?
|
Drug Administration Schedule | 7 | 2021 | 4933 | 0.300 |
Why?
|
Diagnostic Techniques, Cardiovascular | 2 | 2020 | 153 | 0.300 |
Why?
|
Up-Regulation | 8 | 2021 | 4217 | 0.300 |
Why?
|
Data Interpretation, Statistical | 7 | 2018 | 2716 | 0.290 |
Why?
|
Flavins | 2 | 2023 | 17 | 0.290 |
Why?
|
Algorithms | 5 | 2020 | 13881 | 0.290 |
Why?
|
Dementia | 5 | 2022 | 2518 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2018 | 3923 | 0.290 |
Why?
|
Acute Disease | 13 | 2022 | 7149 | 0.290 |
Why?
|
Protein Precursors | 4 | 2020 | 1154 | 0.290 |
Why?
|
Blindness | 3 | 2006 | 617 | 0.290 |
Why?
|
Acute Kidney Injury | 7 | 2024 | 1972 | 0.290 |
Why?
|
Angina Pectoris | 3 | 2015 | 977 | 0.290 |
Why?
|
Guanylate Cyclase | 3 | 2020 | 201 | 0.280 |
Why?
|
Analgesics | 2 | 2008 | 1040 | 0.280 |
Why?
|
Glucose | 7 | 2023 | 4397 | 0.280 |
Why?
|
AIDS-Related Opportunistic Infections | 5 | 2008 | 657 | 0.280 |
Why?
|
Brazil | 4 | 2019 | 1270 | 0.280 |
Why?
|
Cardiac Resynchronization Therapy Devices | 7 | 2019 | 124 | 0.280 |
Why?
|
C-Reactive Protein | 8 | 2024 | 3778 | 0.280 |
Why?
|
Sepsis | 2 | 2022 | 2593 | 0.280 |
Why?
|
Aldosterone | 6 | 2022 | 877 | 0.280 |
Why?
|
Kidney Function Tests | 5 | 2017 | 684 | 0.270 |
Why?
|
Body Weight | 5 | 2016 | 4669 | 0.270 |
Why?
|
Vascular Resistance | 5 | 2016 | 936 | 0.270 |
Why?
|
Brain Ischemia | 2 | 2019 | 3265 | 0.270 |
Why?
|
Young Adult | 30 | 2023 | 56430 | 0.270 |
Why?
|
Thiazepines | 1 | 2005 | 30 | 0.270 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 5867 | 0.270 |
Why?
|
International Classification of Diseases | 2 | 2021 | 867 | 0.270 |
Why?
|
Peptides | 7 | 2020 | 4409 | 0.270 |
Why?
|
Guideline Adherence | 2 | 2018 | 2266 | 0.260 |
Why?
|
Reference Values | 11 | 2019 | 4982 | 0.260 |
Why?
|
Luciferases | 3 | 2023 | 733 | 0.260 |
Why?
|
Pneumonia | 3 | 2024 | 2133 | 0.260 |
Why?
|
Aortic Valve Insufficiency | 2 | 2022 | 579 | 0.260 |
Why?
|
Triglycerides | 4 | 2021 | 2454 | 0.260 |
Why?
|
Cholesterol | 5 | 2021 | 2917 | 0.260 |
Why?
|
Case-Control Studies | 11 | 2020 | 21746 | 0.260 |
Why?
|
Aortic Valve Stenosis | 2 | 2018 | 1965 | 0.260 |
Why?
|
Iron | 4 | 2022 | 1774 | 0.260 |
Why?
|
Epoetin Alfa | 2 | 2022 | 83 | 0.260 |
Why?
|
Hyperglycemia | 3 | 2020 | 1373 | 0.250 |
Why?
|
Insulin Resistance | 2 | 2021 | 3864 | 0.250 |
Why?
|
Coronary Artery Bypass | 4 | 2022 | 2289 | 0.250 |
Why?
|
Eye Diseases | 2 | 2021 | 669 | 0.250 |
Why?
|
Myocardial Reperfusion | 3 | 2006 | 351 | 0.250 |
Why?
|
Diabetic Foot | 1 | 2008 | 355 | 0.250 |
Why?
|
Longitudinal Studies | 14 | 2021 | 13989 | 0.250 |
Why?
|
Age Distribution | 8 | 2018 | 2902 | 0.240 |
Why?
|
Sodium-Glucose Transport Proteins | 1 | 2024 | 12 | 0.240 |
Why?
|
Sweden | 4 | 2020 | 1345 | 0.240 |
Why?
|
Creatine | 1 | 2006 | 421 | 0.240 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2645 | 0.240 |
Why?
|
Neoplasms | 6 | 2023 | 21683 | 0.240 |
Why?
|
Adolescent | 46 | 2023 | 85781 | 0.240 |
Why?
|
Adenomatous Polyps | 1 | 2005 | 107 | 0.240 |
Why?
|
Proteinuria | 2 | 2009 | 658 | 0.240 |
Why?
|
Coronary Vessels | 2 | 2013 | 3107 | 0.240 |
Why?
|
Alginates | 2 | 2015 | 252 | 0.240 |
Why?
|
Probability | 3 | 2021 | 2505 | 0.240 |
Why?
|
Sequoia | 1 | 2023 | 6 | 0.240 |
Why?
|
Digoxin | 2 | 2022 | 250 | 0.240 |
Why?
|
Dihydropyridines | 1 | 2023 | 67 | 0.230 |
Why?
|
Pulmonary Circulation | 3 | 2024 | 739 | 0.230 |
Why?
|
Pyrans | 1 | 2023 | 54 | 0.230 |
Why?
|
Purinergic P2Y Receptor Agonists | 1 | 2023 | 4 | 0.230 |
Why?
|
Contraceptive Agents | 1 | 2005 | 151 | 0.230 |
Why?
|
Sensitivity and Specificity | 12 | 2021 | 14722 | 0.230 |
Why?
|
Hypovolemia | 1 | 2023 | 45 | 0.230 |
Why?
|
Administration, Oral | 7 | 2020 | 3913 | 0.230 |
Why?
|
Retinal Diseases | 2 | 2006 | 683 | 0.230 |
Why?
|
Vitamins | 1 | 2012 | 1622 | 0.230 |
Why?
|
Cost-Benefit Analysis | 6 | 2024 | 5391 | 0.220 |
Why?
|
Prostheses and Implants | 3 | 2019 | 1387 | 0.220 |
Why?
|
Drug Monitoring | 2 | 2020 | 956 | 0.220 |
Why?
|
Blood Specimen Collection | 2 | 2004 | 246 | 0.220 |
Why?
|
Endothelium | 2 | 2020 | 778 | 0.220 |
Why?
|
Erythrocyte Indices | 1 | 2023 | 146 | 0.220 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2005 | 371 | 0.220 |
Why?
|
Frail Elderly | 2 | 2018 | 693 | 0.220 |
Why?
|
Headache Disorders | 2 | 2005 | 130 | 0.220 |
Why?
|
Mineralocorticoids | 1 | 2022 | 38 | 0.220 |
Why?
|
Diagnostic Imaging | 3 | 2015 | 3507 | 0.210 |
Why?
|
Odds Ratio | 12 | 2019 | 9849 | 0.210 |
Why?
|
Serologic Tests | 1 | 2004 | 374 | 0.210 |
Why?
|
Sexual Behavior | 3 | 2009 | 2057 | 0.210 |
Why?
|
Phenotype | 12 | 2023 | 16365 | 0.210 |
Why?
|
Sarcomeres | 3 | 2019 | 374 | 0.210 |
Why?
|
Carotid Arteries | 5 | 2016 | 952 | 0.210 |
Why?
|
Disease Management | 4 | 2019 | 2459 | 0.210 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2008 | 2232 | 0.210 |
Why?
|
Myosins | 3 | 1994 | 409 | 0.210 |
Why?
|
Cardiomyopathy, Hypertrophic, Familial | 1 | 2002 | 66 | 0.210 |
Why?
|
Vitamin D Deficiency | 1 | 2012 | 1343 | 0.210 |
Why?
|
Atrial Flutter | 2 | 2022 | 263 | 0.210 |
Why?
|
Serum Amyloid P-Component | 1 | 2022 | 47 | 0.210 |
Why?
|
Education, Medical | 1 | 2014 | 1721 | 0.210 |
Why?
|
Gene Expression | 2 | 2015 | 7799 | 0.200 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2009 | 1130 | 0.200 |
Why?
|
Medication Therapy Management | 2 | 2021 | 127 | 0.200 |
Why?
|
Carboxylic Acids | 1 | 2022 | 97 | 0.200 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 15519 | 0.200 |
Why?
|
Positron-Emission Tomography | 4 | 2022 | 6234 | 0.200 |
Why?
|
Terminology as Topic | 2 | 2020 | 1547 | 0.200 |
Why?
|
Panophthalmitis | 1 | 2001 | 6 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2014 | 882 | 0.200 |
Why?
|
Erythropoiesis | 2 | 2023 | 705 | 0.200 |
Why?
|
Rhizopus | 1 | 2001 | 21 | 0.200 |
Why?
|
Russia | 6 | 2018 | 408 | 0.200 |
Why?
|
Drug Resistance, Viral | 1 | 2006 | 820 | 0.200 |
Why?
|
Prosthesis Implantation | 3 | 2023 | 642 | 0.190 |
Why?
|
Brain Injury, Chronic | 1 | 2001 | 68 | 0.190 |
Why?
|
Horner Syndrome | 1 | 2001 | 37 | 0.190 |
Why?
|
Hematologic Neoplasms | 2 | 2023 | 1832 | 0.190 |
Why?
|
Societies, Medical | 5 | 2021 | 3743 | 0.190 |
Why?
|
Transplantation Conditioning | 5 | 2019 | 1598 | 0.190 |
Why?
|
Bone Density Conservation Agents | 3 | 2013 | 773 | 0.190 |
Why?
|
Amlodipine | 3 | 2010 | 83 | 0.190 |
Why?
|
Consensus | 8 | 2022 | 2959 | 0.190 |
Why?
|
Alzheimer Disease | 1 | 2021 | 8037 | 0.190 |
Why?
|
Fibroblast Growth Factors | 2 | 2019 | 879 | 0.190 |
Why?
|
Sumatriptan | 2 | 1998 | 65 | 0.190 |
Why?
|
American Heart Association | 2 | 2015 | 1056 | 0.190 |
Why?
|
Amyloidogenic Proteins | 1 | 2021 | 152 | 0.190 |
Why?
|
Foot Ulcer | 1 | 2000 | 59 | 0.190 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2023 | 272 | 0.180 |
Why?
|
Head Injuries, Closed | 1 | 2001 | 136 | 0.180 |
Why?
|
Income | 2 | 2019 | 1913 | 0.180 |
Why?
|
Trigeminal Nerve Diseases | 1 | 2001 | 55 | 0.180 |
Why?
|
Tachycardia | 2 | 2013 | 619 | 0.180 |
Why?
|
Kidney Transplantation | 5 | 2017 | 4251 | 0.180 |
Why?
|
Insulin | 4 | 2019 | 6580 | 0.180 |
Why?
|
Finite Element Analysis | 2 | 2001 | 431 | 0.180 |
Why?
|
Data Collection | 4 | 2018 | 3341 | 0.180 |
Why?
|
Mucormycosis | 1 | 2001 | 97 | 0.180 |
Why?
|
Edema, Cardiac | 1 | 2019 | 18 | 0.180 |
Why?
|
Galectins | 2 | 2020 | 268 | 0.180 |
Why?
|
Pyrrolidines | 1 | 2022 | 342 | 0.180 |
Why?
|
Vital Capacity | 2 | 2022 | 925 | 0.180 |
Why?
|
Thrombolytic Therapy | 4 | 2009 | 2161 | 0.180 |
Why?
|
Eye Infections, Fungal | 1 | 2001 | 110 | 0.180 |
Why?
|
Virus Diseases | 2 | 2023 | 711 | 0.180 |
Why?
|
Feeding Behavior | 2 | 2011 | 3188 | 0.170 |
Why?
|
Stress, Physiological | 4 | 2015 | 1403 | 0.170 |
Why?
|
Leprostatic Agents | 1 | 1998 | 14 | 0.170 |
Why?
|
Cerebral Infarction | 4 | 2022 | 1011 | 0.170 |
Why?
|
Diabetic Ketoacidosis | 1 | 2022 | 245 | 0.170 |
Why?
|
Hyponatremia | 1 | 2022 | 298 | 0.170 |
Why?
|
Patient Selection | 7 | 2017 | 4215 | 0.170 |
Why?
|
Observer Variation | 6 | 2014 | 2593 | 0.170 |
Why?
|
Mycobacterium leprae | 1 | 1998 | 94 | 0.170 |
Why?
|
Adenoma | 2 | 2006 | 2174 | 0.170 |
Why?
|
Exocytosis | 1 | 2020 | 353 | 0.170 |
Why?
|
Cystatin C | 4 | 2023 | 250 | 0.170 |
Why?
|
Calcium Channel Blockers | 4 | 2023 | 690 | 0.160 |
Why?
|
Oxygen Consumption | 4 | 2020 | 1869 | 0.160 |
Why?
|
Statistics as Topic | 8 | 2020 | 2373 | 0.160 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.160 |
Why?
|
Paraneoplastic Syndromes | 1 | 1999 | 151 | 0.160 |
Why?
|
Atrial Appendage | 1 | 2022 | 283 | 0.160 |
Why?
|
Biological Availability | 1 | 2019 | 397 | 0.160 |
Why?
|
Brain Infarction | 2 | 2018 | 299 | 0.160 |
Why?
|
Peripheral Arterial Disease | 2 | 2023 | 1188 | 0.160 |
Why?
|
Sexually Transmitted Diseases | 3 | 2009 | 624 | 0.160 |
Why?
|
Drug Substitution | 2 | 2021 | 281 | 0.160 |
Why?
|
Lipoproteins, LDL | 1 | 2021 | 640 | 0.160 |
Why?
|
Pacemaker, Artificial | 3 | 2019 | 816 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 489 | 0.150 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2020 | 336 | 0.150 |
Why?
|
Workflow | 1 | 2022 | 847 | 0.150 |
Why?
|
Canrenone | 1 | 2017 | 4 | 0.150 |
Why?
|
Immunization Schedule | 1 | 2019 | 221 | 0.150 |
Why?
|
Digitalis Glycosides | 1 | 2017 | 47 | 0.150 |
Why?
|
Colorectal Neoplasms | 3 | 2006 | 6773 | 0.150 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 218 | 0.150 |
Why?
|
Brachial Artery | 2 | 2016 | 369 | 0.150 |
Why?
|
Propanolamines | 1 | 2018 | 167 | 0.150 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 3870 | 0.150 |
Why?
|
Glucuronidase | 1 | 2019 | 207 | 0.150 |
Why?
|
Computer Simulation | 3 | 2021 | 6196 | 0.150 |
Why?
|
Chromosomes, Human, Pair 14 | 5 | 2000 | 299 | 0.150 |
Why?
|
Torsion, Mechanical | 1 | 2017 | 17 | 0.150 |
Why?
|
HIV-1 | 4 | 2012 | 6939 | 0.150 |
Why?
|
Menstruation Disturbances | 1 | 1998 | 148 | 0.150 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2015 | 1813 | 0.150 |
Why?
|
Infusions, Intravenous | 2 | 2019 | 2274 | 0.150 |
Why?
|
Residence Characteristics | 3 | 2019 | 2050 | 0.150 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 441 | 0.150 |
Why?
|
Public-Private Sector Partnerships | 1 | 2018 | 121 | 0.140 |
Why?
|
Georgia (Republic) | 4 | 2018 | 41 | 0.140 |
Why?
|
Risk Reduction Behavior | 5 | 2018 | 1125 | 0.140 |
Why?
|
Lipoproteins, HDL | 1 | 2021 | 638 | 0.140 |
Why?
|
Pleural Effusion | 1 | 2020 | 338 | 0.140 |
Why?
|
Sodium-Glucose Transporter 2 | 3 | 2022 | 85 | 0.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 3255 | 0.140 |
Why?
|
von Willebrand Factor | 1 | 2020 | 669 | 0.140 |
Why?
|
Foot Deformities, Acquired | 1 | 1996 | 27 | 0.140 |
Why?
|
Serine Endopeptidases | 2 | 2020 | 1072 | 0.140 |
Why?
|
Geriatric Assessment | 3 | 2019 | 1372 | 0.140 |
Why?
|
Sickle Cell Trait | 1 | 2016 | 81 | 0.140 |
Why?
|
Medicare | 9 | 2024 | 6566 | 0.140 |
Why?
|
Patient Dropouts | 2 | 2016 | 421 | 0.140 |
Why?
|
Gout | 1 | 2023 | 573 | 0.140 |
Why?
|
Photography | 1 | 2019 | 520 | 0.140 |
Why?
|
Unsafe Sex | 2 | 2008 | 220 | 0.140 |
Why?
|
Dogs | 2 | 2020 | 3912 | 0.140 |
Why?
|
Atrial Function, Right | 1 | 2015 | 33 | 0.140 |
Why?
|
Renal Insufficiency | 2 | 2016 | 804 | 0.140 |
Why?
|
Patients | 3 | 2021 | 900 | 0.140 |
Why?
|
Preventive Health Services | 1 | 2021 | 575 | 0.140 |
Why?
|
Nutrition Assessment | 1 | 2019 | 723 | 0.140 |
Why?
|
Apolipoproteins E | 1 | 2021 | 1438 | 0.140 |
Why?
|
Oligonucleotides, Antisense | 1 | 2018 | 433 | 0.140 |
Why?
|
Fibrosis | 3 | 2023 | 2029 | 0.140 |
Why?
|
Leukoencephalopathies | 1 | 2018 | 238 | 0.130 |
Why?
|
Goals | 1 | 2021 | 706 | 0.130 |
Why?
|
Folic Acid | 2 | 2014 | 1300 | 0.130 |
Why?
|
Activities of Daily Living | 3 | 2023 | 2418 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 629 | 0.130 |
Why?
|
Models, Statistical | 4 | 2020 | 5102 | 0.130 |
Why?
|
Amyloid | 1 | 2020 | 795 | 0.130 |
Why?
|
Geography | 2 | 2015 | 669 | 0.130 |
Why?
|
Waiting Lists | 1 | 2020 | 692 | 0.130 |
Why?
|
Clinical Laboratory Techniques | 2 | 2012 | 738 | 0.130 |
Why?
|
beta-Fructofuranosidase | 1 | 2015 | 13 | 0.130 |
Why?
|
Genetic Linkage | 7 | 2001 | 2421 | 0.130 |
Why?
|
Treatment Failure | 6 | 2020 | 2618 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2021 | 570 | 0.130 |
Why?
|
Nonprescription Drugs | 1 | 1996 | 116 | 0.130 |
Why?
|
Crops, Agricultural | 1 | 2015 | 36 | 0.130 |
Why?
|
Diabetic Retinopathy | 3 | 2018 | 1210 | 0.130 |
Why?
|
Peripheral Nerves | 1 | 1998 | 466 | 0.130 |
Why?
|
Diabetic Neuropathies | 1 | 2018 | 400 | 0.130 |
Why?
|
Patient Compliance | 3 | 2020 | 2684 | 0.130 |
Why?
|
Hybridization, Genetic | 1 | 2015 | 109 | 0.130 |
Why?
|
Medical Records | 2 | 2019 | 1413 | 0.130 |
Why?
|
Total Quality Management | 1 | 1996 | 274 | 0.130 |
Why?
|
Uncertainty | 1 | 2020 | 734 | 0.130 |
Why?
|
Glucosyltransferases | 1 | 2015 | 98 | 0.130 |
Why?
|
Confidence Intervals | 5 | 2012 | 2971 | 0.130 |
Why?
|
Vasoconstrictor Agents | 1 | 1998 | 642 | 0.120 |
Why?
|
Avoidance Learning | 1 | 2016 | 233 | 0.120 |
Why?
|
Polymorphism, Genetic | 4 | 2019 | 4328 | 0.120 |
Why?
|
Pneumococcal Vaccines | 1 | 2018 | 391 | 0.120 |
Why?
|
Elastic Modulus | 2 | 2013 | 214 | 0.120 |
Why?
|
Arthrodesis | 1 | 1996 | 189 | 0.120 |
Why?
|
Anti-HIV Agents | 4 | 2009 | 4256 | 0.120 |
Why?
|
Health Services Accessibility | 2 | 2008 | 5137 | 0.120 |
Why?
|
Logistic Models | 9 | 2019 | 13408 | 0.120 |
Why?
|
Drug Design | 2 | 2017 | 1076 | 0.120 |
Why?
|
Arsenicals | 1 | 2014 | 124 | 0.120 |
Why?
|
Heart Auscultation | 1 | 2014 | 37 | 0.120 |
Why?
|
Dihydroergotamine | 1 | 1994 | 20 | 0.120 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1200 | 0.120 |
Why?
|
Leisure Activities | 1 | 2016 | 311 | 0.120 |
Why?
|
Least-Squares Analysis | 3 | 2020 | 379 | 0.120 |
Why?
|
ROC Curve | 5 | 2019 | 3527 | 0.120 |
Why?
|
Injections, Subcutaneous | 2 | 2018 | 666 | 0.120 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2014 | 964 | 0.120 |
Why?
|
Diet Surveys | 1 | 2018 | 1173 | 0.120 |
Why?
|
Gene Expression Regulation, Plant | 1 | 2015 | 201 | 0.120 |
Why?
|
Intention to Treat Analysis | 3 | 2021 | 426 | 0.120 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.120 |
Why?
|
Hemorrhage | 2 | 2023 | 3461 | 0.120 |
Why?
|
Ventricular Function | 3 | 2013 | 416 | 0.120 |
Why?
|
Famotidine | 1 | 1993 | 16 | 0.120 |
Why?
|
Cimetidine | 1 | 1993 | 78 | 0.120 |
Why?
|
Hepatitis C Antibodies | 1 | 2014 | 145 | 0.120 |
Why?
|
Tissue Survival | 1 | 2014 | 118 | 0.120 |
Why?
|
Kansas | 2 | 2023 | 39 | 0.120 |
Why?
|
Resuscitation | 2 | 2011 | 658 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 35421 | 0.120 |
Why?
|
Mutation | 8 | 2019 | 29786 | 0.120 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2012 | 1873 | 0.120 |
Why?
|
Ambulatory Care | 2 | 2016 | 2708 | 0.120 |
Why?
|
Stress, Mechanical | 6 | 2017 | 1686 | 0.120 |
Why?
|
Liver | 5 | 2023 | 7474 | 0.120 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2013 | 72 | 0.120 |
Why?
|
Respiratory Sounds | 3 | 2016 | 696 | 0.120 |
Why?
|
Echocardiography, Stress | 1 | 2014 | 131 | 0.120 |
Why?
|
Forced Expiratory Volume | 1 | 2018 | 1743 | 0.110 |
Why?
|
HIV | 1 | 2001 | 1604 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2004 | 3022 | 0.110 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2021 | 3523 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2124 | 0.110 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2014 | 236 | 0.110 |
Why?
|
Secondary Prevention | 4 | 2015 | 1530 | 0.110 |
Why?
|
Second Messenger Systems | 1 | 2013 | 206 | 0.110 |
Why?
|
Immunoglobulin Light Chains | 1 | 2014 | 277 | 0.110 |
Why?
|
Cerebrovascular Disorders | 3 | 1992 | 1504 | 0.110 |
Why?
|
Mendelian Randomization Analysis | 1 | 2018 | 967 | 0.110 |
Why?
|
Periodicals as Topic | 2 | 2022 | 1432 | 0.110 |
Why?
|
Oxides | 1 | 2014 | 405 | 0.110 |
Why?
|
Hemorheology | 1 | 2013 | 145 | 0.110 |
Why?
|
Patient Admission | 2 | 2019 | 1380 | 0.110 |
Why?
|
Serotonin Receptor Agonists | 2 | 1993 | 152 | 0.110 |
Why?
|
Fluorobenzenes | 1 | 2014 | 183 | 0.110 |
Why?
|
Muscle Cells | 2 | 2014 | 197 | 0.110 |
Why?
|
Medicine | 1 | 2021 | 946 | 0.110 |
Why?
|
Creatine Kinase | 3 | 2006 | 694 | 0.110 |
Why?
|
Patient Readmission | 5 | 2020 | 3114 | 0.110 |
Why?
|
Rural Health Services | 2 | 2008 | 379 | 0.110 |
Why?
|
Drug Costs | 1 | 2020 | 1105 | 0.110 |
Why?
|
Endothelium, Vascular | 2 | 2019 | 4456 | 0.110 |
Why?
|
Heterozygote | 3 | 2016 | 2804 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 783 | 0.110 |
Why?
|
Down-Regulation | 1 | 2020 | 3002 | 0.110 |
Why?
|
Cyclic GMP | 1 | 2013 | 409 | 0.110 |
Why?
|
Independent Living | 1 | 2016 | 568 | 0.110 |
Why?
|
Waist Circumference | 1 | 2016 | 917 | 0.110 |
Why?
|
Government | 2 | 2023 | 165 | 0.110 |
Why?
|
Information Dissemination | 2 | 2021 | 1099 | 0.110 |
Why?
|
Thromboembolism | 2 | 2016 | 986 | 0.100 |
Why?
|
Regression Analysis | 4 | 2018 | 6459 | 0.100 |
Why?
|
Drug Therapy | 1 | 2015 | 497 | 0.100 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2013 | 314 | 0.100 |
Why?
|
Influenza A virus | 1 | 2015 | 456 | 0.100 |
Why?
|
Cyclophosphamide | 2 | 2016 | 2242 | 0.100 |
Why?
|
Anticoagulants | 6 | 2023 | 4599 | 0.100 |
Why?
|
Hydrochlorothiazide | 2 | 2010 | 98 | 0.100 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2012 | 143 | 0.100 |
Why?
|
Credentialing | 1 | 2012 | 126 | 0.100 |
Why?
|
Life Expectancy | 2 | 2015 | 1184 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2000 | 1401 | 0.100 |
Why?
|
Drug Resistance | 1 | 2018 | 1609 | 0.100 |
Why?
|
Causality | 2 | 2016 | 1275 | 0.100 |
Why?
|
Angiotensin II | 5 | 2006 | 881 | 0.100 |
Why?
|
Area Under Curve | 2 | 2018 | 1654 | 0.100 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 2 | 2023 | 149 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 697 | 0.100 |
Why?
|
Phospholipases A2, Secretory | 1 | 2011 | 31 | 0.100 |
Why?
|
Cell Wall | 1 | 2015 | 422 | 0.100 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 1997 | 4266 | 0.100 |
Why?
|
Editorial Policies | 1 | 2016 | 451 | 0.100 |
Why?
|
Life Change Events | 1 | 1997 | 938 | 0.100 |
Why?
|
Disease-Free Survival | 7 | 2019 | 6895 | 0.100 |
Why?
|
Europe, Eastern | 2 | 2023 | 75 | 0.100 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2012 | 264 | 0.100 |
Why?
|
Statistics, Nonparametric | 4 | 2012 | 2886 | 0.100 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2003 | 272 | 0.100 |
Why?
|
Vaccines, Inactivated | 2 | 2023 | 184 | 0.100 |
Why?
|
Retinal Vein | 1 | 1991 | 47 | 0.100 |
Why?
|
Malaria | 1 | 2021 | 1239 | 0.100 |
Why?
|
Depression | 5 | 2021 | 7766 | 0.100 |
Why?
|
Child | 21 | 2023 | 77709 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 725 | 0.100 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2012 | 126 | 0.100 |
Why?
|
Electrocardiography, Ambulatory | 3 | 2021 | 585 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 5 | 2023 | 17446 | 0.100 |
Why?
|
Catheter Ablation | 3 | 2020 | 2758 | 0.100 |
Why?
|
Life Style | 3 | 2018 | 3835 | 0.090 |
Why?
|
Animals | 35 | 2020 | 168757 | 0.090 |
Why?
|
Demography | 2 | 2013 | 1656 | 0.090 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2012 | 378 | 0.090 |
Why?
|
Inflammation | 4 | 2024 | 10638 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2795 | 0.090 |
Why?
|
Optic Atrophy | 1 | 1991 | 79 | 0.090 |
Why?
|
Hyperhomocysteinemia | 1 | 2011 | 124 | 0.090 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 2010 | 49 | 0.090 |
Why?
|
Mitral Valve Annuloplasty | 1 | 2012 | 143 | 0.090 |
Why?
|
Phenylalanine | 1 | 2012 | 365 | 0.090 |
Why?
|
Exercise Test | 5 | 2017 | 2074 | 0.090 |
Why?
|
Endothelial Cells | 1 | 2023 | 3479 | 0.090 |
Why?
|
Women's Health | 1 | 2000 | 2034 | 0.090 |
Why?
|
RNA Interference | 1 | 2019 | 2889 | 0.090 |
Why?
|
Species Specificity | 1 | 2015 | 2478 | 0.090 |
Why?
|
Sensation | 1 | 1992 | 336 | 0.090 |
Why?
|
Atrial Function | 1 | 2010 | 107 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 3 | 2015 | 5535 | 0.090 |
Why?
|
Anterior Wall Myocardial Infarction | 1 | 2010 | 45 | 0.090 |
Why?
|
Placebo Effect | 3 | 2019 | 502 | 0.090 |
Why?
|
Choice Behavior | 1 | 2016 | 803 | 0.090 |
Why?
|
Amyloid beta-Peptides | 2 | 2020 | 3587 | 0.090 |
Why?
|
Radiation Monitoring | 1 | 2010 | 98 | 0.090 |
Why?
|
Organizational Policy | 1 | 2012 | 429 | 0.090 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 980 | 0.090 |
Why?
|
Benzazepines | 2 | 2010 | 326 | 0.090 |
Why?
|
Gyrus Cinguli | 1 | 2016 | 1091 | 0.090 |
Why?
|
Forecasting | 2 | 2016 | 2951 | 0.090 |
Why?
|
Myosin Heavy Chains | 2 | 2002 | 414 | 0.090 |
Why?
|
Nerve Compression Syndromes | 1 | 1991 | 160 | 0.090 |
Why?
|
Macular Edema | 2 | 2012 | 359 | 0.090 |
Why?
|
Bacteria | 1 | 2000 | 2114 | 0.090 |
Why?
|
Radon | 1 | 2010 | 81 | 0.090 |
Why?
|
Serum Albumin | 2 | 2009 | 676 | 0.090 |
Why?
|
Ethylene Glycols | 2 | 2020 | 156 | 0.090 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 871 | 0.090 |
Why?
|
Sulfones | 1 | 2012 | 437 | 0.090 |
Why?
|
Lipoprotein(a) | 1 | 2013 | 435 | 0.090 |
Why?
|
Benzoates | 1 | 2011 | 217 | 0.090 |
Why?
|
Heart-Assist Devices | 3 | 2018 | 1194 | 0.090 |
Why?
|
Frontal Lobe | 1 | 2016 | 1406 | 0.090 |
Why?
|
Procollagen | 2 | 2023 | 185 | 0.090 |
Why?
|
Aspartame | 1 | 1989 | 18 | 0.090 |
Why?
|
Lung Diseases | 1 | 2019 | 1886 | 0.090 |
Why?
|
Hypercalcemia | 1 | 2012 | 409 | 0.090 |
Why?
|
Trinidad and Tobago | 1 | 2008 | 11 | 0.090 |
Why?
|
Choroid | 1 | 1991 | 322 | 0.080 |
Why?
|
Blood Urea Nitrogen | 3 | 2024 | 191 | 0.080 |
Why?
|
Genotype | 5 | 2017 | 12951 | 0.080 |
Why?
|
Analysis of Variance | 7 | 2014 | 6365 | 0.080 |
Why?
|
Safety | 2 | 2006 | 1186 | 0.080 |
Why?
|
Dilatation, Pathologic | 1 | 2010 | 520 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1379 | 0.080 |
Why?
|
Calcinosis | 1 | 2018 | 1499 | 0.080 |
Why?
|
Equipment Design | 3 | 2014 | 3582 | 0.080 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2012 | 397 | 0.080 |
Why?
|
Probucol | 1 | 2008 | 23 | 0.080 |
Why?
|
Vitamin B Complex | 1 | 2011 | 288 | 0.080 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2001 | 403 | 0.080 |
Why?
|
Syndrome | 2 | 2014 | 3251 | 0.080 |
Why?
|
Adrenomedullin | 2 | 2023 | 87 | 0.080 |
Why?
|
Attention | 2 | 2016 | 2400 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1107 | 0.080 |
Why?
|
Angiography | 1 | 2014 | 1639 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1956 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7785 | 0.080 |
Why?
|
Withholding Treatment | 1 | 2013 | 599 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2003 | 689 | 0.080 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1814 | 0.080 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 2031 | 0.080 |
Why?
|
Albumins | 1 | 2011 | 569 | 0.080 |
Why?
|
Contrast Sensitivity | 1 | 2009 | 244 | 0.080 |
Why?
|
Genetic Testing | 1 | 2021 | 3444 | 0.080 |
Why?
|
Tissue Plasminogen Activator | 2 | 1999 | 1261 | 0.080 |
Why?
|
Natriuresis | 3 | 1977 | 124 | 0.080 |
Why?
|
Length of Stay | 5 | 2019 | 6309 | 0.080 |
Why?
|
Medication Adherence | 2 | 2017 | 2063 | 0.080 |
Why?
|
Bronchodilator Agents | 2 | 2010 | 502 | 0.080 |
Why?
|
Hydrothorax | 1 | 2007 | 16 | 0.080 |
Why?
|
Uranium | 1 | 2007 | 19 | 0.080 |
Why?
|
Epoprostenol | 1 | 1989 | 254 | 0.080 |
Why?
|
Heart Transplantation | 2 | 2020 | 3110 | 0.080 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2023 | 472 | 0.080 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2023 | 340 | 0.080 |
Why?
|
Radial Artery | 1 | 2009 | 194 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1519 | 0.080 |
Why?
|
Cytokines | 3 | 2020 | 7322 | 0.080 |
Why?
|
Self Efficacy | 2 | 2023 | 616 | 0.080 |
Why?
|
Survivors | 4 | 2014 | 2291 | 0.080 |
Why?
|
Optic Nerve Diseases | 1 | 1991 | 327 | 0.080 |
Why?
|
Molecular Sequence Data | 9 | 2015 | 18111 | 0.080 |
Why?
|
Transplantation, Homologous | 5 | 2021 | 4776 | 0.080 |
Why?
|
Blood Proteins | 3 | 2020 | 1124 | 0.080 |
Why?
|
Air Pollutants, Radioactive | 1 | 2007 | 46 | 0.070 |
Why?
|
Arteries | 1 | 2012 | 1119 | 0.070 |
Why?
|
Wine | 1 | 2008 | 165 | 0.070 |
Why?
|
Genetic Variation | 2 | 2023 | 6544 | 0.070 |
Why?
|
Amaurosis Fugax | 1 | 2006 | 7 | 0.070 |
Why?
|
Anticarcinogenic Agents | 1 | 2009 | 253 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4751 | 0.070 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2007 | 127 | 0.070 |
Why?
|
Rats | 19 | 2004 | 24260 | 0.070 |
Why?
|
Manometry | 1 | 2009 | 445 | 0.070 |
Why?
|
Ascomycota | 1 | 2007 | 82 | 0.070 |
Why?
|
Syncope | 1 | 2010 | 429 | 0.070 |
Why?
|
Piperazines | 2 | 2014 | 2488 | 0.070 |
Why?
|
Latin America | 2 | 2018 | 381 | 0.070 |
Why?
|
Biocompatible Materials | 1 | 2015 | 1736 | 0.070 |
Why?
|
Cross Infection | 1 | 1996 | 1416 | 0.070 |
Why?
|
Vision Disorders | 2 | 1992 | 1058 | 0.070 |
Why?
|
Enzyme Inhibitors | 4 | 2023 | 3798 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2017 | 4149 | 0.070 |
Why?
|
Psychology | 1 | 2008 | 356 | 0.070 |
Why?
|
Endothelin-1 | 2 | 2023 | 314 | 0.070 |
Why?
|
Electrolytes | 1 | 2007 | 282 | 0.070 |
Why?
|
Gastrointestinal Diseases | 2 | 2013 | 1170 | 0.070 |
Why?
|
Hospitals | 2 | 2021 | 3952 | 0.070 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2007 | 164 | 0.070 |
Why?
|
Mental Recall | 3 | 1996 | 1205 | 0.070 |
Why?
|
Gastrointestinal Tract | 2 | 2013 | 814 | 0.070 |
Why?
|
Aniline Compounds | 3 | 2020 | 986 | 0.070 |
Why?
|
Hematologic Tests | 1 | 2007 | 240 | 0.070 |
Why?
|
Bombesin | 1 | 1986 | 34 | 0.070 |
Why?
|
Genome-Wide Association Study | 3 | 2022 | 12261 | 0.070 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2007 | 233 | 0.070 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3610 | 0.070 |
Why?
|
Heart Septum | 2 | 2012 | 313 | 0.070 |
Why?
|
Fibrin | 1 | 1989 | 506 | 0.070 |
Why?
|
Motion | 2 | 2010 | 798 | 0.070 |
Why?
|
Feasibility Studies | 4 | 2023 | 5078 | 0.070 |
Why?
|
Calibration | 1 | 2008 | 816 | 0.070 |
Why?
|
Liver Function Tests | 1 | 2007 | 528 | 0.070 |
Why?
|
Space Perception | 1 | 2009 | 475 | 0.070 |
Why?
|
Luteal Phase | 1 | 2006 | 147 | 0.070 |
Why?
|
Follicular Phase | 1 | 2006 | 153 | 0.070 |
Why?
|
Cell Fusion | 1 | 2006 | 297 | 0.070 |
Why?
|
Propranolol | 4 | 1983 | 502 | 0.070 |
Why?
|
Asia | 2 | 2018 | 610 | 0.070 |
Why?
|
Drug-Eluting Stents | 1 | 2012 | 753 | 0.070 |
Why?
|
Quality Improvement | 1 | 2021 | 3749 | 0.070 |
Why?
|
Epidemiologic Methods | 4 | 2016 | 1364 | 0.070 |
Why?
|
Chromosome Mapping | 6 | 2001 | 4740 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9274 | 0.070 |
Why?
|
Hexuronic Acids | 2 | 2015 | 144 | 0.070 |
Why?
|
Glucuronic Acid | 2 | 2015 | 148 | 0.070 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 2356 | 0.070 |
Why?
|
Ventricular Dysfunction | 1 | 2006 | 143 | 0.070 |
Why?
|
Molecular Targeted Therapy | 2 | 2014 | 2727 | 0.070 |
Why?
|
Obesity, Morbid | 1 | 2016 | 1213 | 0.070 |
Why?
|
Magnetic Resonance Angiography | 1 | 2012 | 1442 | 0.070 |
Why?
|
Sample Size | 3 | 2015 | 845 | 0.070 |
Why?
|
Pregnancy | 7 | 2023 | 29144 | 0.070 |
Why?
|
Sodium, Dietary | 2 | 2006 | 418 | 0.060 |
Why?
|
South America | 2 | 2016 | 181 | 0.060 |
Why?
|
Pedigree | 8 | 2009 | 4644 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2012 | 1801 | 0.060 |
Why?
|
beta 2-Microglobulin | 2 | 2017 | 315 | 0.060 |
Why?
|
Public Health Informatics | 1 | 2006 | 110 | 0.060 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2006 | 235 | 0.060 |
Why?
|
Thinness | 1 | 2008 | 480 | 0.060 |
Why?
|
Myocardial Reperfusion Injury | 2 | 2005 | 476 | 0.060 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1987 | 648 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3752 | 0.060 |
Why?
|
Aspirin | 3 | 2010 | 3282 | 0.060 |
Why?
|
BRCA2 Protein | 1 | 2009 | 794 | 0.060 |
Why?
|
Adrenal Glands | 4 | 1991 | 546 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2019 | 3537 | 0.060 |
Why?
|
Mannose-Binding Lectin | 1 | 2005 | 150 | 0.060 |
Why?
|
Sexual Partners | 3 | 2008 | 730 | 0.060 |
Why?
|
Methyldopa | 1 | 1983 | 20 | 0.060 |
Why?
|
Tricuspid Valve | 1 | 2007 | 403 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2371 | 0.060 |
Why?
|
Environmental Monitoring | 1 | 2010 | 1414 | 0.060 |
Why?
|
Diagnosis, Differential | 5 | 2001 | 12959 | 0.060 |
Why?
|
Nerve Net | 1 | 2016 | 2174 | 0.060 |
Why?
|
Disasters | 1 | 1990 | 511 | 0.060 |
Why?
|
Heme Oxygenase (Decyclizing) | 1 | 2004 | 171 | 0.060 |
Why?
|
Disopyramide | 1 | 2023 | 16 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 547 | 0.060 |
Why?
|
Graft Rejection | 1 | 2017 | 4397 | 0.060 |
Why?
|
Pulmonary Artery | 1 | 2012 | 1912 | 0.060 |
Why?
|
Databases as Topic | 1 | 2006 | 475 | 0.060 |
Why?
|
Tomography, Spiral Computed | 1 | 2005 | 280 | 0.060 |
Why?
|
Netherlands | 2 | 2020 | 2170 | 0.060 |
Why?
|
Postoperative Complications | 3 | 2017 | 15295 | 0.060 |
Why?
|
HIV Seropositivity | 2 | 2009 | 971 | 0.060 |
Why?
|
Carcinoma, Small Cell | 1 | 1986 | 420 | 0.060 |
Why?
|
Atmosphere | 1 | 2023 | 33 | 0.060 |
Why?
|
Health Behavior | 2 | 2019 | 2636 | 0.060 |
Why?
|
Graft vs Leukemia Effect | 1 | 2003 | 111 | 0.060 |
Why?
|
Hemagglutination Inhibition Tests | 1 | 2023 | 77 | 0.060 |
Why?
|
Electric Stimulation Therapy | 1 | 1989 | 605 | 0.060 |
Why?
|
Smoking Cessation | 2 | 2018 | 2071 | 0.060 |
Why?
|
Brain | 2 | 2020 | 26385 | 0.060 |
Why?
|
Heterosexuality | 1 | 2005 | 276 | 0.060 |
Why?
|
Health Care Costs | 2 | 2012 | 3209 | 0.060 |
Why?
|
Blood Volume | 3 | 2010 | 565 | 0.060 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 2022 | 44 | 0.050 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2006 | 615 | 0.050 |
Why?
|
Leukocyte Elastase | 1 | 2003 | 113 | 0.050 |
Why?
|
Photic Stimulation | 1 | 2009 | 2025 | 0.050 |
Why?
|
Combined Modality Therapy | 4 | 2019 | 8642 | 0.050 |
Why?
|
Commerce | 1 | 2008 | 592 | 0.050 |
Why?
|
Medically Underserved Area | 1 | 2004 | 253 | 0.050 |
Why?
|
Microcirculation | 2 | 2023 | 1286 | 0.050 |
Why?
|
Angina, Unstable | 3 | 2015 | 926 | 0.050 |
Why?
|
Receptors, Erythropoietin | 1 | 2022 | 147 | 0.050 |
Why?
|
Vidarabine | 1 | 2003 | 345 | 0.050 |
Why?
|
Drug Synergism | 2 | 2003 | 1792 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6770 | 0.050 |
Why?
|
Atrial Premature Complexes | 1 | 2021 | 17 | 0.050 |
Why?
|
Colchicine | 1 | 2023 | 243 | 0.050 |
Why?
|
Reperfusion | 1 | 2023 | 284 | 0.050 |
Why?
|
Ganciclovir | 1 | 2002 | 258 | 0.050 |
Why?
|
Sclerosis | 1 | 2022 | 213 | 0.050 |
Why?
|
Receptors, Interleukin-1 | 1 | 2002 | 262 | 0.050 |
Why?
|
Acyclovir | 1 | 2002 | 272 | 0.050 |
Why?
|
Nervous System Diseases | 1 | 1992 | 1622 | 0.050 |
Why?
|
Eye Evisceration | 1 | 2001 | 23 | 0.050 |
Why?
|
Electronics | 1 | 2023 | 322 | 0.050 |
Why?
|
Rare Diseases | 1 | 2006 | 553 | 0.050 |
Why?
|
Diagnostic Techniques, Urological | 1 | 2001 | 28 | 0.050 |
Why?
|
Psychomotor Agitation | 1 | 2023 | 293 | 0.050 |
Why?
|
Suppuration | 1 | 2000 | 56 | 0.050 |
Why?
|
Nitrogen Oxides | 1 | 2021 | 129 | 0.050 |
Why?
|
Receptors, Transferrin | 1 | 2022 | 296 | 0.050 |
Why?
|
Attitude to Health | 2 | 2008 | 2052 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2014 | 3068 | 0.050 |
Why?
|
Schools | 1 | 2009 | 1433 | 0.050 |
Why?
|
Biomedical Research | 1 | 2016 | 3309 | 0.050 |
Why?
|
Defensins | 3 | 1999 | 35 | 0.050 |
Why?
|
Bilirubin | 1 | 2022 | 425 | 0.050 |
Why?
|
Transplantation Immunology | 1 | 2003 | 546 | 0.050 |
Why?
|
Pigment Epithelium of Eye | 1 | 2001 | 220 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2015 | 3336 | 0.050 |
Why?
|
Video Recording | 2 | 2010 | 949 | 0.050 |
Why?
|
AIDS Serodiagnosis | 1 | 2001 | 184 | 0.050 |
Why?
|
Antioxidants | 1 | 2008 | 1663 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2012 | 3589 | 0.050 |
Why?
|
Blood Flow Velocity | 2 | 2014 | 1423 | 0.050 |
Why?
|
Los Angeles | 1 | 2020 | 238 | 0.040 |
Why?
|
Indomethacin | 2 | 1992 | 332 | 0.040 |
Why?
|
Action Potentials | 2 | 2019 | 1806 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2023 | 434 | 0.040 |
Why?
|
Health Policy | 1 | 2012 | 2661 | 0.040 |
Why?
|
Antilymphocyte Serum | 1 | 2021 | 492 | 0.040 |
Why?
|
Cardiomyopathy, Alcoholic | 1 | 2019 | 6 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3638 | 0.040 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1990 | 6038 | 0.040 |
Why?
|
Jugular Veins | 1 | 2020 | 204 | 0.040 |
Why?
|
Gentamicins | 1 | 2000 | 255 | 0.040 |
Why?
|
Histamine Release | 1 | 1999 | 142 | 0.040 |
Why?
|
Porphyrins | 1 | 2001 | 348 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 1990 | 768 | 0.040 |
Why?
|
Photons | 2 | 2001 | 588 | 0.040 |
Why?
|
Asia, Western | 1 | 2018 | 20 | 0.040 |
Why?
|
Dangerous Behavior | 1 | 2019 | 66 | 0.040 |
Why?
|
Drug Resistance, Microbial | 1 | 2022 | 862 | 0.040 |
Why?
|
Tachycardia, Supraventricular | 1 | 2021 | 263 | 0.040 |
Why?
|
Chromatography, Gel | 3 | 1996 | 668 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1155 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2022 | 780 | 0.040 |
Why?
|
Asia, Southeastern | 1 | 2018 | 111 | 0.040 |
Why?
|
Quebec | 1 | 2018 | 134 | 0.040 |
Why?
|
Drug Prescriptions | 1 | 2008 | 1637 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2023 | 789 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 4 | 2009 | 2559 | 0.040 |
Why?
|
Americas | 1 | 2018 | 111 | 0.040 |
Why?
|
Hypersensitivity, Immediate | 1 | 2001 | 337 | 0.040 |
Why?
|
Rats, Wistar | 2 | 1999 | 1901 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2021 | 648 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2009 | 2212 | 0.040 |
Why?
|
Collagenases | 1 | 1999 | 228 | 0.040 |
Why?
|
Diuresis | 2 | 1975 | 116 | 0.040 |
Why?
|
Health Surveys | 1 | 2008 | 4037 | 0.040 |
Why?
|
Policy | 1 | 2022 | 508 | 0.040 |
Why?
|
Genes | 3 | 1993 | 1893 | 0.040 |
Why?
|
Marriage | 1 | 2000 | 339 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2008 | 2278 | 0.040 |
Why?
|
Pro-Opiomelanocortin | 2 | 1991 | 163 | 0.040 |
Why?
|
Choroidal Neovascularization | 1 | 2001 | 343 | 0.040 |
Why?
|
Vectorcardiography | 1 | 2018 | 43 | 0.040 |
Why?
|
Conditioning, Classical | 2 | 2016 | 366 | 0.040 |
Why?
|
Developing Countries | 2 | 2022 | 2815 | 0.040 |
Why?
|
alpha-Defensins | 2 | 1999 | 28 | 0.040 |
Why?
|
Peripartum Period | 1 | 2019 | 133 | 0.040 |
Why?
|
Polysomnography | 2 | 2015 | 1776 | 0.040 |
Why?
|
Coronary Angiography | 4 | 2017 | 4577 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1999 | 326 | 0.040 |
Why?
|
Thiazoles | 2 | 2016 | 1483 | 0.040 |
Why?
|
Penicillins | 1 | 2000 | 380 | 0.040 |
Why?
|
Precipitating Factors | 1 | 2017 | 52 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2503 | 0.040 |
Why?
|
Memory | 2 | 1987 | 2174 | 0.040 |
Why?
|
Research Personnel | 1 | 2022 | 573 | 0.040 |
Why?
|
Eye Neoplasms | 1 | 1999 | 313 | 0.040 |
Why?
|
Reperfusion Injury | 1 | 2004 | 1026 | 0.040 |
Why?
|
Hypophysectomy | 1 | 1977 | 113 | 0.040 |
Why?
|
HIV Protease Inhibitors | 1 | 2000 | 430 | 0.040 |
Why?
|
Vena Cava, Inferior | 1 | 2020 | 440 | 0.040 |
Why?
|
Photosensitizing Agents | 1 | 2001 | 602 | 0.040 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2018 | 127 | 0.040 |
Why?
|
Donor Selection | 1 | 2019 | 201 | 0.040 |
Why?
|
Kidney Tubules, Proximal | 3 | 1992 | 416 | 0.040 |
Why?
|
Public Health | 2 | 2020 | 2603 | 0.040 |
Why?
|
Water-Electrolyte Balance | 2 | 1975 | 346 | 0.040 |
Why?
|
Egg Shell | 1 | 1996 | 8 | 0.040 |
Why?
|
Mitral Valve Prolapse | 1 | 1999 | 231 | 0.040 |
Why?
|
Weight Loss | 1 | 2008 | 2622 | 0.040 |
Why?
|
Femur Head Necrosis | 1 | 1997 | 132 | 0.040 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2001 | 1320 | 0.040 |
Why?
|
Albuterol | 1 | 1997 | 208 | 0.040 |
Why?
|
Diet | 1 | 2015 | 7939 | 0.040 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 1997 | 202 | 0.040 |
Why?
|
Models, Biological | 1 | 2013 | 9583 | 0.040 |
Why?
|
Chagas Disease | 1 | 2018 | 166 | 0.040 |
Why?
|
Blotting, Western | 1 | 2004 | 5179 | 0.040 |
Why?
|
alpha-Fetoproteins | 1 | 1977 | 224 | 0.040 |
Why?
|
Ontario | 1 | 2017 | 383 | 0.040 |
Why?
|
Calcium Carbonate | 1 | 1996 | 67 | 0.040 |
Why?
|
Research Report | 1 | 2019 | 355 | 0.040 |
Why?
|
Fluorine Radioisotopes | 1 | 2019 | 442 | 0.040 |
Why?
|
Paired-Associate Learning | 1 | 1996 | 52 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2022 | 1877 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2005 | 1889 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1041 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1660 | 0.030 |
Why?
|
Prolactin | 2 | 1993 | 669 | 0.030 |
Why?
|
Glomerulonephritis | 1 | 2018 | 372 | 0.030 |
Why?
|
Radionuclide Ventriculography | 1 | 2015 | 41 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2006 | 1715 | 0.030 |
Why?
|
Gait Disorders, Neurologic | 1 | 2018 | 231 | 0.030 |
Why?
|
Fundus Oculi | 2 | 2001 | 473 | 0.030 |
Why?
|
Japan | 1 | 2020 | 1360 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2022 | 6622 | 0.030 |
Why?
|
Mesenchymal Stem Cells | 1 | 2006 | 1632 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 2002 | 820 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 13695 | 0.030 |
Why?
|
Expert Testimony | 1 | 2018 | 356 | 0.030 |
Why?
|
Killer Cells, Natural | 4 | 1993 | 2133 | 0.030 |
Why?
|
Animals, Newborn | 2 | 2002 | 2726 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1036 | 0.030 |
Why?
|
Histocompatibility | 1 | 2016 | 330 | 0.030 |
Why?
|
Spirometry | 1 | 2018 | 864 | 0.030 |
Why?
|
Disease Models, Animal | 7 | 2014 | 18029 | 0.030 |
Why?
|
International Cooperation | 2 | 2013 | 1420 | 0.030 |
Why?
|
Lymphocytes | 2 | 2019 | 2617 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2016 | 647 | 0.030 |
Why?
|
Photochemotherapy | 1 | 2001 | 807 | 0.030 |
Why?
|
Attitude to Death | 1 | 1998 | 382 | 0.030 |
Why?
|
Radiology | 1 | 2009 | 2100 | 0.030 |
Why?
|
Infant | 4 | 2022 | 35136 | 0.030 |
Why?
|
Information Services | 1 | 1996 | 244 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 1991 | 1572 | 0.030 |
Why?
|
Pilot Projects | 3 | 2009 | 8324 | 0.030 |
Why?
|
Death Certificates | 1 | 2015 | 169 | 0.030 |
Why?
|
Confusion | 1 | 2016 | 275 | 0.030 |
Why?
|
Thrombosis | 1 | 2008 | 2968 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3843 | 0.030 |
Why?
|
Rats, Inbred Strains | 3 | 1992 | 2186 | 0.030 |
Why?
|
Compliance | 1 | 2014 | 104 | 0.030 |
Why?
|
Amnesia | 1 | 2016 | 248 | 0.030 |
Why?
|
Chickens | 1 | 1996 | 865 | 0.030 |
Why?
|
Stochastic Processes | 1 | 2015 | 344 | 0.030 |
Why?
|
Seasons | 1 | 2020 | 1493 | 0.030 |
Why?
|
Face | 1 | 2020 | 994 | 0.030 |
Why?
|
Fluoroscopy | 2 | 2013 | 924 | 0.030 |
Why?
|
Social Perception | 1 | 1998 | 425 | 0.030 |
Why?
|
Edema | 1 | 2018 | 789 | 0.030 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2014 | 109 | 0.030 |
Why?
|
Neutrophils | 2 | 1999 | 3719 | 0.030 |
Why?
|
History, 21st Century | 1 | 2020 | 1534 | 0.030 |
Why?
|
Eosinophils | 1 | 1998 | 955 | 0.030 |
Why?
|
Prenatal Care | 1 | 2001 | 1092 | 0.030 |
Why?
|
Antithrombins | 1 | 2016 | 304 | 0.030 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2014 | 101 | 0.030 |
Why?
|
Genes, Dominant | 2 | 2000 | 880 | 0.030 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2014 | 177 | 0.030 |
Why?
|
Drug Approval | 1 | 2020 | 742 | 0.030 |
Why?
|
Sodium Channel Blockers | 1 | 2014 | 176 | 0.030 |
Why?
|
Heart Defects, Congenital | 1 | 2010 | 4584 | 0.030 |
Why?
|
USSR | 1 | 2012 | 21 | 0.030 |
Why?
|
Lipocalins | 1 | 2014 | 170 | 0.030 |
Why?
|
Cosyntropin | 1 | 1993 | 33 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 5 | 2015 | 20129 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2022 | 7181 | 0.030 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2016 | 271 | 0.030 |
Why?
|
Aorta | 2 | 2014 | 2061 | 0.030 |
Why?
|
Aggression | 1 | 1998 | 753 | 0.030 |
Why?
|
Hand Deformities, Congenital | 1 | 1994 | 146 | 0.030 |
Why?
|
Lod Score | 2 | 1990 | 614 | 0.030 |
Why?
|
Diclofenac | 1 | 2013 | 71 | 0.030 |
Why?
|
Heart Septal Defects | 1 | 1994 | 192 | 0.030 |
Why?
|
Naproxen | 1 | 2013 | 99 | 0.030 |
Why?
|
Cell Cycle | 1 | 2001 | 2967 | 0.030 |
Why?
|
Flavoproteins | 1 | 1992 | 43 | 0.030 |
Why?
|
Cotinine | 1 | 1993 | 206 | 0.030 |
Why?
|
Personnel Selection | 1 | 2014 | 189 | 0.030 |
Why?
|
Fluorescein Angiography | 2 | 2001 | 940 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 1994 | 552 | 0.030 |
Why?
|
Injections | 1 | 2015 | 840 | 0.030 |
Why?
|
Asthma | 3 | 2001 | 6011 | 0.030 |
Why?
|
Anthracyclines | 1 | 2014 | 288 | 0.030 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1994 | 462 | 0.030 |
Why?
|
Semantics | 1 | 1996 | 584 | 0.030 |
Why?
|
Cell Division | 3 | 2003 | 4568 | 0.030 |
Why?
|
Hydrodynamics | 1 | 2013 | 158 | 0.030 |
Why?
|
Acetaminophen | 1 | 1996 | 545 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2740 | 0.030 |
Why?
|
Amino Acid Sequence | 8 | 2000 | 13815 | 0.030 |
Why?
|
Ergot Alkaloids | 1 | 1991 | 12 | 0.030 |
Why?
|
Lung Neoplasms | 2 | 1987 | 13102 | 0.030 |
Why?
|
Mast Cells | 1 | 1999 | 1544 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1375 | 0.030 |
Why?
|
Aqueous Humor | 1 | 2012 | 161 | 0.030 |
Why?
|
Succinate Dehydrogenase | 1 | 1992 | 146 | 0.030 |
Why?
|
Tumor Cells, Cultured | 3 | 2003 | 6314 | 0.030 |
Why?
|
Hypertrophy | 1 | 2013 | 569 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 973 | 0.030 |
Why?
|
Ergotamine | 1 | 1991 | 7 | 0.030 |
Why?
|
Pyridones | 1 | 2016 | 712 | 0.030 |
Why?
|
Israel | 1 | 2014 | 796 | 0.030 |
Why?
|
Heart Injuries | 1 | 2013 | 210 | 0.030 |
Why?
|
Mothers | 1 | 2022 | 2165 | 0.030 |
Why?
|
Ibuprofen | 1 | 2013 | 236 | 0.030 |
Why?
|
Heparin | 1 | 1999 | 1637 | 0.030 |
Why?
|
Massachusetts | 2 | 2015 | 8663 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3176 | 0.020 |
Why?
|
Clinical Enzyme Tests | 1 | 2011 | 115 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2531 | 0.020 |
Why?
|
Codon | 1 | 1993 | 611 | 0.020 |
Why?
|
Rabbits | 4 | 1999 | 4894 | 0.020 |
Why?
|
Health Services | 1 | 1997 | 758 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1477 | 0.020 |
Why?
|
Hematocrit | 2 | 1988 | 636 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2019 | 1486 | 0.020 |
Why?
|
Pain | 1 | 2006 | 4986 | 0.020 |
Why?
|
Skin Diseases | 1 | 2000 | 1065 | 0.020 |
Why?
|
Proteins | 2 | 1999 | 6103 | 0.020 |
Why?
|
Infant, Newborn | 3 | 2022 | 25625 | 0.020 |
Why?
|
Drug Industry | 1 | 2017 | 746 | 0.020 |
Why?
|
Myosin Subfragments | 1 | 1990 | 21 | 0.020 |
Why?
|
Receptors, Cell Surface | 2 | 2016 | 2866 | 0.020 |
Why?
|
Alpha Particles | 1 | 2010 | 26 | 0.020 |
Why?
|
Genes, Fungal | 1 | 1992 | 455 | 0.020 |
Why?
|
Scotoma | 1 | 1992 | 139 | 0.020 |
Why?
|
Ophthalmic Solutions | 1 | 2012 | 317 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 551 | 0.020 |
Why?
|
Outpatient Clinics, Hospital | 1 | 1993 | 392 | 0.020 |
Why?
|
Bone Marrow | 2 | 2019 | 2948 | 0.020 |
Why?
|
Chromosome Banding | 1 | 1990 | 278 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1993 | 1681 | 0.020 |
Why?
|
Analog-Digital Conversion | 1 | 2010 | 23 | 0.020 |
Why?
|
Automation | 1 | 2013 | 584 | 0.020 |
Why?
|
Polyethylene Terephthalates | 1 | 2010 | 116 | 0.020 |
Why?
|
Body Fluids | 3 | 2007 | 319 | 0.020 |
Why?
|
Radioimmunoassay | 2 | 1993 | 919 | 0.020 |
Why?
|
Glycopeptides | 1 | 2011 | 224 | 0.020 |
Why?
|
Dehydroepiandrosterone | 1 | 1991 | 252 | 0.020 |
Why?
|
Missouri | 1 | 1990 | 117 | 0.020 |
Why?
|
Echocardiography, Transesophageal | 1 | 2016 | 1133 | 0.020 |
Why?
|
Radiosurgery | 1 | 2000 | 1329 | 0.020 |
Why?
|
Vitreous Body | 1 | 2012 | 389 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2018 | 1179 | 0.020 |
Why?
|
Critical Illness | 1 | 2023 | 2670 | 0.020 |
Why?
|
Hydrogels | 1 | 2015 | 724 | 0.020 |
Why?
|
Oligonucleotide Probes | 1 | 1990 | 427 | 0.020 |
Why?
|
Depressive Disorder | 2 | 1995 | 3748 | 0.020 |
Why?
|
Genetic Markers | 3 | 2002 | 2634 | 0.020 |
Why?
|
Escherichia coli | 1 | 2022 | 4217 | 0.020 |
Why?
|
Australia | 1 | 2013 | 1170 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2007 | 8949 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2002 | 2987 | 0.020 |
Why?
|
Nature | 1 | 2009 | 15 | 0.020 |
Why?
|
Cells, Cultured | 5 | 2006 | 19229 | 0.020 |
Why?
|
Green Fluorescent Proteins | 2 | 2006 | 2088 | 0.020 |
Why?
|
Hallucinations | 1 | 1992 | 360 | 0.020 |
Why?
|
Office Visits | 1 | 1994 | 598 | 0.020 |
Why?
|
Dioxins | 1 | 1990 | 102 | 0.020 |
Why?
|
Cytochalasins | 1 | 1989 | 19 | 0.020 |
Why?
|
Trifluoperazine | 1 | 1989 | 40 | 0.020 |
Why?
|
Regional Blood Flow | 2 | 2007 | 1525 | 0.020 |
Why?
|
Reward | 1 | 2016 | 941 | 0.020 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 1989 | 83 | 0.020 |
Why?
|
Hearing Loss, Sensorineural | 1 | 1995 | 770 | 0.020 |
Why?
|
Perceptual Masking | 1 | 2009 | 94 | 0.020 |
Why?
|
Cytochalasin D | 1 | 1989 | 92 | 0.020 |
Why?
|
Fear | 1 | 1998 | 1440 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2004 | 7880 | 0.020 |
Why?
|
Saliva | 1 | 1993 | 809 | 0.020 |
Why?
|
Drug Discovery | 1 | 2017 | 1058 | 0.020 |
Why?
|
Puerto Rico | 1 | 1990 | 356 | 0.020 |
Why?
|
Perioperative Care | 1 | 2016 | 1002 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2001 | 2214 | 0.020 |
Why?
|
Secretory Rate | 1 | 1968 | 82 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2006 | 11483 | 0.020 |
Why?
|
Ethanol | 2 | 2001 | 1342 | 0.020 |
Why?
|
Fibrinolytic Agents | 1 | 1999 | 2158 | 0.020 |
Why?
|
Hydrocortisone | 2 | 1993 | 1826 | 0.020 |
Why?
|
Schizophrenic Psychology | 1 | 1996 | 1678 | 0.020 |
Why?
|
Cycloheximide | 1 | 1989 | 347 | 0.020 |
Why?
|
Dactinomycin | 1 | 1989 | 318 | 0.020 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 1992 | 356 | 0.020 |
Why?
|
Joint Instability | 1 | 1996 | 792 | 0.020 |
Why?
|
Trichomonas Vaginitis | 1 | 2008 | 35 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
Pituitary Gland | 1 | 1991 | 665 | 0.020 |
Why?
|
Point Mutation | 1 | 1994 | 1623 | 0.020 |
Why?
|
Databases, Factual | 2 | 2017 | 7729 | 0.020 |
Why?
|
Umbilical Veins | 1 | 1989 | 433 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2019 | 1901 | 0.020 |
Why?
|
Motivation | 1 | 1998 | 1971 | 0.020 |
Why?
|
Sensory Thresholds | 1 | 2009 | 391 | 0.020 |
Why?
|
South Africa | 1 | 2013 | 1731 | 0.020 |
Why?
|
Walking | 1 | 2015 | 1180 | 0.020 |
Why?
|
Nephrons | 3 | 1977 | 220 | 0.020 |
Why?
|
Phospholipases A2 | 1 | 2007 | 203 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2014 | 906 | 0.020 |
Why?
|
Condoms | 1 | 2009 | 323 | 0.020 |
Why?
|
Tobacco Smoke Pollution | 1 | 1993 | 816 | 0.020 |
Why?
|
Blood Vessels | 1 | 2013 | 1125 | 0.020 |
Why?
|
Herpes Genitalis | 1 | 2008 | 141 | 0.020 |
Why?
|
Vinblastine | 1 | 1989 | 502 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2494 | 0.020 |
Why?
|
Mining | 1 | 2007 | 88 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2008 | 189 | 0.020 |
Why?
|
Necrosis | 1 | 2011 | 1643 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 3 | 2004 | 8301 | 0.020 |
Why?
|
Wechsler Scales | 1 | 1987 | 260 | 0.020 |
Why?
|
Menstruation | 1 | 1968 | 302 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2013 | 1265 | 0.020 |
Why?
|
Spouses | 1 | 2009 | 286 | 0.020 |
Why?
|
Lipids | 1 | 2018 | 3305 | 0.020 |
Why?
|
Graft Survival | 1 | 2017 | 3737 | 0.020 |
Why?
|
Arteriosclerosis | 1 | 2011 | 1092 | 0.020 |
Why?
|
Nucleosides | 1 | 1987 | 138 | 0.020 |
Why?
|
Pleura | 1 | 2007 | 235 | 0.020 |
Why?
|
Shock, Septic | 1 | 2013 | 775 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2019 | 3679 | 0.020 |
Why?
|
Structure-Activity Relationship | 2 | 1992 | 3129 | 0.020 |
Why?
|
Corticosterone | 1 | 1987 | 310 | 0.020 |
Why?
|
Pulsatile Flow | 1 | 2007 | 332 | 0.020 |
Why?
|
Syphilis | 1 | 2008 | 227 | 0.020 |
Why?
|
Solubility | 1 | 2007 | 1085 | 0.020 |
Why?
|
Complement C2 | 1 | 2005 | 72 | 0.020 |
Why?
|
Complement Factor D | 1 | 2005 | 68 | 0.020 |
Why?
|
Complement Pathway, Mannose-Binding Lectin | 1 | 2005 | 29 | 0.020 |
Why?
|
Renal Circulation | 1 | 2006 | 333 | 0.020 |
Why?
|
Family Practice | 1 | 1968 | 516 | 0.020 |
Why?
|
Complement Factor B | 1 | 2005 | 72 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2001 | 4253 | 0.020 |
Why?
|
Complement Pathway, Classical | 1 | 2005 | 97 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2010 | 1254 | 0.020 |
Why?
|
Drug Interactions | 1 | 2010 | 1460 | 0.020 |
Why?
|
Hospitals, Special | 1 | 2006 | 101 | 0.020 |
Why?
|
Complement C1q | 1 | 2005 | 92 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1997 | 2104 | 0.020 |
Why?
|
Models, Psychological | 1 | 2009 | 811 | 0.020 |
Why?
|
Elasticity | 1 | 2007 | 657 | 0.020 |
Why?
|
Complement Pathway, Alternative | 1 | 2005 | 126 | 0.020 |
Why?
|
Delirium | 1 | 2016 | 1609 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2010 | 1182 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 610 | 0.020 |
Why?
|
Random Allocation | 1 | 1989 | 2429 | 0.020 |
Why?
|
Base Sequence | 5 | 1994 | 12797 | 0.020 |
Why?
|
Peer Group | 1 | 2009 | 635 | 0.020 |
Why?
|
Life Tables | 1 | 2004 | 370 | 0.020 |
Why?
|
Hydroxides | 1 | 1984 | 47 | 0.020 |
Why?
|
Immunoglobulin E | 2 | 2001 | 1463 | 0.020 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 1999 | 362 | 0.010 |
Why?
|
Muscle Contraction | 1 | 1989 | 1240 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 1738 | 0.010 |
Why?
|
Age of Onset | 2 | 2005 | 3271 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 1993 | 1676 | 0.010 |
Why?
|
Cerebral Hemorrhage | 2 | 2006 | 2647 | 0.010 |
Why?
|
Observation | 1 | 2006 | 312 | 0.010 |
Why?
|
Integrases | 1 | 2006 | 533 | 0.010 |
Why?
|
Risk-Taking | 1 | 2009 | 986 | 0.010 |
Why?
|
Retroviridae | 1 | 2006 | 914 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1991 | 1257 | 0.010 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2003 | 38 | 0.010 |
Why?
|
Brain Mapping | 2 | 2016 | 6669 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9313 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2003 | 257 | 0.010 |
Why?
|
Amino Acids | 2 | 1987 | 1736 | 0.010 |
Why?
|
Sodium Chloride | 2 | 1976 | 625 | 0.010 |
Why?
|
Urban Health | 1 | 2006 | 547 | 0.010 |
Why?
|
Biological Assay | 1 | 1987 | 652 | 0.010 |
Why?
|
Disclosure | 1 | 2009 | 736 | 0.010 |
Why?
|
Psychometrics | 2 | 1990 | 3002 | 0.010 |
Why?
|
Nuclease Protection Assays | 1 | 2002 | 16 | 0.010 |
Why?
|
Homeostasis | 1 | 2014 | 3340 | 0.010 |
Why?
|
Immunoblotting | 1 | 2006 | 1682 | 0.010 |
Why?
|
Psychotherapy | 1 | 1992 | 1643 | 0.010 |
Why?
|
Phorbol Esters | 1 | 2002 | 111 | 0.010 |
Why?
|
Occupational Exposure | 1 | 1993 | 1796 | 0.010 |
Why?
|
Cognition Disorders | 1 | 2017 | 4043 | 0.010 |
Why?
|
Hepatitis B | 1 | 2008 | 695 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1850 | 0.010 |
Why?
|
Femoral Artery | 1 | 2007 | 845 | 0.010 |
Why?
|
Mice, Inbred C57BL | 3 | 2006 | 21827 | 0.010 |
Why?
|
Health Education | 1 | 2009 | 1056 | 0.010 |
Why?
|
Gadolinium DTPA | 1 | 2006 | 836 | 0.010 |
Why?
|
Isoantigens | 1 | 1984 | 567 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2002 | 152 | 0.010 |
Why?
|
Metabolism | 1 | 1963 | 196 | 0.010 |
Why?
|
Paracrine Communication | 1 | 2003 | 277 | 0.010 |
Why?
|
Heme Oxygenase-1 | 1 | 2004 | 381 | 0.010 |
Why?
|
Acetic Acid | 1 | 2001 | 55 | 0.010 |
Why?
|
Diet, Sodium-Restricted | 1 | 1963 | 287 | 0.010 |
Why?
|
Giant Cell Arteritis | 1 | 1985 | 292 | 0.010 |
Why?
|
Cyclin D | 1 | 2001 | 71 | 0.010 |
Why?
|
Receptors, Interleukin | 1 | 2002 | 245 | 0.010 |
Why?
|
Viral Matrix Proteins | 1 | 2002 | 186 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2004 | 853 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 1992 | 2752 | 0.010 |
Why?
|
Infusions, Intra-Arterial | 1 | 2001 | 234 | 0.010 |
Why?
|
Nonmuscle Myosin Type IIB | 1 | 2000 | 20 | 0.010 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2006 | 496 | 0.010 |
Why?
|
Blotting, Southern | 2 | 1993 | 803 | 0.010 |
Why?
|
Psychological Tests | 1 | 1983 | 651 | 0.010 |
Why?
|
Verbal Learning | 1 | 1983 | 467 | 0.010 |
Why?
|
Growth Substances | 1 | 2003 | 784 | 0.010 |
Why?
|
Parents | 1 | 2014 | 3407 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2029 | 0.010 |
Why?
|
Kinetics | 1 | 1989 | 6473 | 0.010 |
Why?
|
Cyclin E | 1 | 2001 | 172 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1991 | 2731 | 0.010 |
Why?
|
Yttrium Radioisotopes | 1 | 2001 | 93 | 0.010 |
Why?
|
Quality of Health Care | 1 | 1996 | 4371 | 0.010 |
Why?
|
Artifacts | 1 | 2009 | 1904 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 3 | 1993 | 1369 | 0.010 |
Why?
|
Viral Load | 1 | 2009 | 3299 | 0.010 |
Why?
|
Virus Activation | 1 | 2002 | 319 | 0.010 |
Why?
|
Mass Screening | 2 | 2009 | 5255 | 0.010 |
Why?
|
Radiation Injuries, Experimental | 1 | 2000 | 91 | 0.010 |
Why?
|
Clone Cells | 1 | 2003 | 1692 | 0.010 |
Why?
|
Virulence Factors, Bordetella | 1 | 1999 | 156 | 0.010 |
Why?
|
Saralasin | 2 | 1976 | 39 | 0.010 |
Why?
|
Pertussis Toxin | 1 | 1999 | 178 | 0.010 |
Why?
|
Skin Tests | 1 | 2001 | 613 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2003 | 1341 | 0.010 |
Why?
|
DNA Primers | 2 | 1994 | 2892 | 0.010 |
Why?
|
Peritoneal Cavity | 1 | 1999 | 148 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2001 | 326 | 0.010 |
Why?
|
17-alpha-Hydroxyprogesterone | 1 | 1958 | 22 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 1992 | 6993 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1999 | 370 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2002 | 1147 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2006 | 1405 | 0.010 |
Why?
|
Cyclins | 1 | 2001 | 603 | 0.010 |
Why?
|
Neuraminidase | 1 | 1999 | 210 | 0.010 |
Why?
|
Lysophospholipids | 1 | 2001 | 331 | 0.010 |
Why?
|
Interleukin-1 | 1 | 2002 | 1263 | 0.010 |
Why?
|
Ischemic Attack, Transient | 1 | 1984 | 935 | 0.010 |
Why?
|
Ultrasonic Therapy | 1 | 2001 | 235 | 0.010 |
Why?
|
Urography | 1 | 2000 | 313 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2009 | 2576 | 0.010 |
Why?
|
Macromolecular Substances | 2 | 1991 | 1454 | 0.010 |
Why?
|
Transfection | 1 | 2006 | 5892 | 0.010 |
Why?
|
Adrenal Cortex | 1 | 1958 | 140 | 0.010 |
Why?
|
Iodine | 1 | 1960 | 286 | 0.010 |
Why?
|
Trypsin | 2 | 1991 | 511 | 0.010 |
Why?
|
Kidney Tubules | 2 | 1977 | 488 | 0.010 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2001 | 671 | 0.010 |
Why?
|
Liver Failure | 1 | 2000 | 241 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2002 | 732 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 1 | 2008 | 1832 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3772 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2006 | 1637 | 0.010 |
Why?
|
Defense Mechanisms | 1 | 1998 | 178 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2002 | 675 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1984 | 1607 | 0.010 |
Why?
|
Guinea Pigs | 1 | 1999 | 1386 | 0.010 |
Why?
|
Radiotherapy, Conformal | 1 | 2001 | 548 | 0.010 |
Why?
|
Urinary Tract | 1 | 2001 | 309 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1984 | 1821 | 0.010 |
Why?
|
Isotonic Solutions | 1 | 1977 | 119 | 0.010 |
Why?
|
Schizophrenia | 1 | 1996 | 6882 | 0.010 |
Why?
|
Punishment | 1 | 1998 | 98 | 0.010 |
Why?
|
Water | 2 | 1977 | 1395 | 0.010 |
Why?
|
HLA Antigens | 1 | 2003 | 1381 | 0.010 |
Why?
|
Alleles | 2 | 1998 | 6933 | 0.010 |
Why?
|
Cloning, Molecular | 2 | 1993 | 4320 | 0.010 |
Why?
|
Iodine Radioisotopes | 1 | 1960 | 1032 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2006 | 3420 | 0.010 |
Why?
|
Imagination | 1 | 1998 | 221 | 0.010 |
Why?
|
Family Health | 1 | 2001 | 1282 | 0.010 |
Why?
|
Lymphoma, Follicular | 1 | 1960 | 435 | 0.010 |
Why?
|
Imidazoles | 1 | 2002 | 1206 | 0.010 |
Why?
|
Edetic Acid | 1 | 1996 | 276 | 0.010 |
Why?
|
Diphenylamine | 1 | 1976 | 50 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 346 | 0.010 |
Why?
|
Curriculum | 1 | 2009 | 3605 | 0.010 |
Why?
|
Pregnancy, Animal | 1 | 1976 | 134 | 0.010 |
Why?
|
Cryosurgery | 1 | 2001 | 453 | 0.010 |
Why?
|
GTP Phosphohydrolases | 1 | 1999 | 509 | 0.010 |
Why?
|
Hypotonic Solutions | 1 | 1975 | 49 | 0.010 |
Why?
|
Tuberculosis | 1 | 2008 | 1912 | 0.010 |
Why?
|
Guanidines | 1 | 1996 | 193 | 0.010 |
Why?
|
Presbycusis | 1 | 1995 | 42 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1999 | 1799 | 0.010 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 1999 | 638 | 0.010 |
Why?
|
Extracellular Space | 1 | 1977 | 594 | 0.010 |
Why?
|
Heme | 1 | 1977 | 307 | 0.010 |
Why?
|
Neoplastic Stem Cells | 1 | 2003 | 1376 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2004 | 12072 | 0.010 |
Why?
|
Vasopressins | 1 | 1976 | 370 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2002 | 2216 | 0.010 |
Why?
|
Audiometry | 1 | 1995 | 241 | 0.010 |
Why?
|
Image Enhancement | 1 | 2006 | 2921 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1998 | 1588 | 0.010 |
Why?
|
Gene Frequency | 1 | 2002 | 3588 | 0.010 |
Why?
|
Glutamine | 1 | 1997 | 578 | 0.010 |
Why?
|
Cell Line | 2 | 2004 | 15997 | 0.010 |
Why?
|
DNA Replication | 1 | 2001 | 1399 | 0.010 |
Why?
|
Kidney Diseases, Cystic | 1 | 1976 | 186 | 0.010 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1996 | 964 | 0.010 |
Why?
|
Eosinophilia | 1 | 1998 | 541 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2001 | 2539 | 0.010 |
Why?
|
Progesterone | 1 | 1958 | 776 | 0.010 |
Why?
|
Macular Degeneration | 1 | 2001 | 980 | 0.010 |
Why?
|
Arginine | 1 | 1997 | 944 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 1801 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2001 | 20822 | 0.010 |
Why?
|
Mice | 3 | 2006 | 81183 | 0.010 |
Why?
|
Delusions | 1 | 1995 | 300 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2002 | 2440 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2002 | 13033 | 0.010 |
Why?
|
Radiotherapy | 1 | 1960 | 1533 | 0.010 |
Why?
|
Enzyme Activation | 1 | 1999 | 3701 | 0.010 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 1993 | 329 | 0.010 |
Why?
|
Evoked Potentials, Auditory | 1 | 1996 | 525 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1960 | 1180 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1960 | 1381 | 0.010 |
Why?
|
Brachytherapy | 1 | 2001 | 1248 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2006 | 11366 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 1997 | 1997 | 0.010 |
Why?
|
Visual Acuity | 1 | 2001 | 2530 | 0.010 |
Why?
|
Contrast Media | 1 | 2006 | 5300 | 0.010 |
Why?
|
Likelihood Functions | 1 | 1995 | 1005 | 0.010 |
Why?
|
Leukemia | 1 | 1960 | 1511 | 0.010 |
Why?
|
Glutamic Acid | 1 | 1997 | 1169 | 0.010 |
Why?
|
Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 31 | 0.010 |
Why?
|
Methysergide | 1 | 1991 | 28 | 0.010 |
Why?
|
T-Lymphocytes | 2 | 1987 | 10180 | 0.010 |
Why?
|
Protein Sorting Signals | 1 | 1992 | 281 | 0.010 |
Why?
|
Immunity, Innate | 1 | 1984 | 2958 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1996 | 2557 | 0.010 |
Why?
|
Glycerol | 1 | 1992 | 278 | 0.010 |
Why?
|
Lymphoma | 1 | 1960 | 1877 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2000 | 2564 | 0.010 |
Why?
|
Politics | 1 | 1998 | 791 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1992 | 1085 | 0.010 |
Why?
|
Androgens | 1 | 1958 | 1281 | 0.010 |
Why?
|
Fetus | 1 | 1958 | 1880 | 0.010 |
Why?
|
Cluster Headache | 1 | 1991 | 54 | 0.010 |
Why?
|
Hip Joint | 1 | 1997 | 1002 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2003 | 3386 | 0.010 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 1991 | 238 | 0.010 |
Why?
|
Hippocampus | 1 | 1983 | 3675 | 0.010 |
Why?
|
Physicians | 1 | 1968 | 4567 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 14557 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 1958 | 1889 | 0.010 |
Why?
|
Phosphorylation | 1 | 2001 | 8436 | 0.010 |
Why?
|
DNA | 2 | 1990 | 7301 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1990 | 878 | 0.010 |
Why?
|
Dopamine | 1 | 1977 | 1591 | 0.010 |
Why?
|
Lymphokines | 1 | 1993 | 949 | 0.010 |
Why?
|
Mutagenesis, Insertional | 1 | 1992 | 655 | 0.010 |
Why?
|
Reaction Time | 1 | 1996 | 2097 | 0.010 |
Why?
|
Sequence Deletion | 1 | 1994 | 1526 | 0.010 |
Why?
|
Norethynodrel | 1 | 1968 | 2 | 0.010 |
Why?
|
Mestranol | 1 | 1968 | 9 | 0.010 |
Why?
|
Pregnanediol | 1 | 1968 | 18 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 4931 | 0.010 |
Why?
|
Molecular Weight | 1 | 1991 | 2255 | 0.010 |
Why?
|
Ascites | 1 | 1971 | 344 | 0.010 |
Why?
|
Deuterium | 1 | 1968 | 101 | 0.010 |
Why?
|
DNA Probes | 1 | 1989 | 560 | 0.010 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 1989 | 380 | 0.010 |
Why?
|
Chemistry, Clinical | 1 | 1968 | 64 | 0.000 |
Why?
|
Sequence Alignment | 1 | 1993 | 2256 | 0.000 |
Why?
|
Students | 1 | 1998 | 1654 | 0.000 |
Why?
|
Erythrocytes | 1 | 1977 | 2455 | 0.000 |
Why?
|
England | 1 | 1968 | 522 | 0.000 |
Why?
|
Perfusion | 1 | 1992 | 1360 | 0.000 |
Why?
|
Cell Separation | 1 | 1993 | 1751 | 0.000 |
Why?
|
Biological Transport | 1 | 1992 | 2118 | 0.000 |
Why?
|
House Calls | 1 | 1968 | 160 | 0.000 |
Why?
|
Diphtheria | 1 | 1947 | 35 | 0.000 |
Why?
|
Ischemia | 1 | 1976 | 1907 | 0.000 |
Why?
|
Spleen | 1 | 1993 | 2362 | 0.000 |
Why?
|
Homosexuality | 1 | 1987 | 262 | 0.000 |
Why?
|
Contraceptives, Oral | 1 | 1968 | 564 | 0.000 |
Why?
|
Cystine | 1 | 1986 | 95 | 0.000 |
Why?
|
Cattle | 1 | 1991 | 3922 | 0.000 |
Why?
|
Protein Multimerization | 1 | 1990 | 970 | 0.000 |
Why?
|
Rosette Formation | 1 | 1984 | 153 | 0.000 |
Why?
|
Child, Preschool | 2 | 2000 | 41006 | 0.000 |
Why?
|
Blood Sedimentation | 1 | 1985 | 231 | 0.000 |
Why?
|
Macrophages | 1 | 1999 | 5655 | 0.000 |
Why?
|
Polymerase Chain Reaction | 1 | 1994 | 6171 | 0.000 |
Why?
|
Disulfides | 1 | 1986 | 457 | 0.000 |
Why?
|
Nictitating Membrane | 1 | 1983 | 9 | 0.000 |
Why?
|
Free Radicals | 1 | 1984 | 237 | 0.000 |
Why?
|
Catalase | 1 | 1984 | 222 | 0.000 |
Why?
|
Arachidonic Acids | 1 | 1984 | 299 | 0.000 |
Why?
|
Autopsy | 1 | 1947 | 1020 | 0.000 |
Why?
|
Scopolamine | 1 | 1983 | 99 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 11524 | 0.000 |
Why?
|
Speech Perception | 1 | 1987 | 489 | 0.000 |
Why?
|
Endopeptidases | 1 | 1986 | 772 | 0.000 |
Why?
|
Sheep | 1 | 1984 | 1437 | 0.000 |
Why?
|
Swine | 1 | 1991 | 5917 | 0.000 |
Why?
|
Superoxide Dismutase | 1 | 1984 | 597 | 0.000 |
Why?
|
Prednisone | 1 | 1985 | 1574 | 0.000 |
Why?
|
Memory, Short-Term | 1 | 1987 | 975 | 0.000 |
Why?
|
Hydrogen Peroxide | 1 | 1984 | 731 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 1996 | 5708 | 0.000 |
Why?
|
Educational Status | 1 | 1987 | 2540 | 0.000 |
Why?
|
Myocarditis | 1 | 1947 | 771 | 0.000 |
Why?
|
Protein Conformation | 1 | 1986 | 4011 | 0.000 |
Why?
|
Loop of Henle | 1 | 1976 | 40 | 0.000 |
Why?
|
Inulin | 1 | 1976 | 84 | 0.000 |
Why?
|
Hydrostatic Pressure | 1 | 1976 | 106 | 0.000 |
Why?
|
Oils | 1 | 1976 | 63 | 0.000 |
Why?
|
Kidney Cortex | 1 | 1976 | 186 | 0.000 |
Why?
|
Software | 1 | 1989 | 4443 | 0.000 |
Why?
|
Uremia | 1 | 1976 | 201 | 0.000 |
Why?
|
Oxygen | 1 | 1984 | 4189 | 0.000 |
Why?
|
Electroencephalography | 1 | 1966 | 6150 | 0.000 |
Why?
|